



10/538704 PCT U03/01664

10 JUN 2005

RECEIVED 20 JAN 2004

WIPO PCT

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

Patent Office Canberra

I, JULİE BILLINGSLEY, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2002953341 for a patent by THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH as filed on 13 December 2002.




WITNESS my hand this Fifteenth day of January 2004

JULIE BILLINGSLEY

TEAM LEADER EXAMINATION

SUPPORT AND SALES



Regulation 3.2

3 888 A

200436

on of sala sombled kerken och fill omre komen broken och bled bled fill sen fill som och blede sala som benedlag bled f

i marin partikina provincia princial artical principal aligna provincia artical principal de la company

SANGER OF THE PROPERTY OF THE

The state of the second of the

Maria Kara William

CANTON CONTROL OF THE SECOND SECTION OF THE SECOND 
1080 N. WW.

u kalende abelga elektre

AUSTRALIA

diala efficie a col

NEW MARKET STATE OF THE PROPERTY OF THE PROPER

richtet auswarden bestelle der Bestelle in der der Bestelle der der der der der der der bestelle der der der d

要表现的主义的主要企业,但是一个企业的企业的企业,但是一个企业,但是一个企业的企业,但是一个企业的企业的企业的企业,但是一个企业的企业,但是一个企业的企业的企业

A DAMESTO DE PORTE EN PORTE ALBERTANTO A SOCIAL DE LA CONTROLES. LA CONTROLES DE LA CONTRATA DEL CONTRATA DE LA CONTRATA DEL CONTRATA DE LA CONTRATA DEL CONTRATA DEL CONTRATA DE LA CONTRATA DE LA CONTRATA DEL CONTRATA DEL CONTRATA DE LA CONTRATA DEL CONTRATA DE LA CONTRATA DEL CO

The Walter and Eliza Hall Institute of Medical Research

nestere, und tree encommente de mille amédité en uté millement misse une celebrate en en le décidir de mais en

MERCHER STATE OF THE SECOND 
Patents Act 1990

PROVISIONAL SPECIFICATION

for the invention entitled:

"A novel phosphoprotein"

The invention is described in the following statement:

tietuse et til beskiete le etter i er elektrikt kant littlet på ett i kritistikkel ekilistikken, elektrikkel e

Charles and the transfer and the second seco

Q:OperEjjhDecember/Dez 2002/2589867,ep,webi.au 147.doc - 13/12/02

ament fill stelle mante del del militar taka deserbi,

กระสมราช ๑๐๘๖๐

The British of Australian Control of the State of the Sta

Transplantina di manistra di manganta d

等国际公司的复数形式 医电影

\$ . \$ .

\$ \$ . t. c.

1000

#### A NOVEL PHOSPHOPROTEIN

# BACKGROUND OF THE INVENTION

## 5 FIELD OF THE INVENTION

The present invention relates generally to cancer therapy and cancer diagnostics and to agents useful therefor. More particularly, the present invention provides a novel tumorigenesis-related phosphoprotein and a nucleic acid molecule encoding same. The 10 present invention also provides diagnostic agents to detect the presence or absence of the tumorigenesis-related phosphoprotein or the presence or absence of an expressible tumorigenesis-related gene encoding the phosphoprotein. Such diagnostic agents are useful ide salsassas ar in determining the likelihood of development of a tumor in a vertebrate animal such as mammal and, in particular, a human. The diagnostic agents provided by the present 15 invention may be used inter alia in screening and/or predicting the likelihood of development of neoplastic diseases such as but not limited to mammary cancer.

#### 各条位。"我是我的"我就从我们,……"我们的**亲爱的**是严重的知识,还是**然**就说道:"我们,这一只是我<mark>我们</mark>我们,我们就是我们,我们就是我们的一个人,这个人也会把这个人 DESCRIPTION OF THE PRIOR ART ero errera estableció i cuarema caso establecar o crasación describó casa en cuardo consectivada en casacidades

20 Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

ande e sometika katalogi. Dogit e e sometika katalogi og til et e e e katalogi et katalogi og til ette som kel Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common 25 general knowledge in any country

The increasing sophistication of recombinant DNA technology is greatly facilitating research and development in the medical and allied health industries. This is particularly the case in relation to genetic and immunologically based diagnostic assays for disease 30 conditions or for determining the propensity for disease conditions to develop.

tikan terta di sebagai dalah mengan tertikan di sebesah bermalah di sebagai dan bermalah di sebesah di sebesah

19/19/03

The genetic bases behind cancer initiation and development are complex and generally involve a network of multiple dominant, positive regulators of oncogenesis (i.e. oncogenes) as well as multiple negative regulators, sometimes referred to as tumor suppressor genes, including, for example, transcription factors and cell-cycle regulators. The genetic complexity of tumor initiation and development requires that further research be conducted to enable the generation of a comprehensive library of oncogenes and tumor suppressor genes to enable a full diagnosis or therapeutic regimen to be implemented. This is particularly the case since it is considered unlikely that a mutation in a single gene will seement of all tumors and the prove to be responsible for the development of all tumors.

The receptor tyrosine kinase ErbB2 was first identified as the mammalian counterpart of the v-erbB oncogene and belongs to the family of ErbB receptors, comprising four members (HER1/EGFR (epidermal growth factor receptor), HER2/ErbB2/Neu, HER3/ErbB3 and HER4/ErbB4). These receptors signal cooperatively by forming ligandinduced combinations of homo- and heterodimers. Over-expression of ErbB1 and ErbB2 is associated with a variety of human cancers. Of particular significance are the amplification and/or over-expression of ErbB2 in up to 30% of human breast cancer patients, in which it correlates with poor prognosis. - 1927年2月1日 - 日本 1989日第88条の201日 - 1931日 - 19

partition and **20** are reconsist all religions from the contraction of 
and the second of the constitution of the second of the se

86.

The importance of the ErbB2 signaling in mammary tumorigenesis has been established using mouse models. Over-expression of Neu, driven off the mouse mammary tumor virus promoter, induced focal mammary tumors which frequently metastasized to the lung (Guy et al., Proc. Natl. Acad. Sci. USA 89. 10578-10582, 1992). The long latency period, 25 however, suggested that additional molecular events were required for tumors to develop. Further analysis of these tumors identified somatic mutations in neu, resulting in constitutive activation of the receptor. The up-regulation of the ErbB3 protein concomitant with an increase in ErbB3 tyrosine phosphorylation in these tumors suggested that ErbB2 synergizes with ErbB3 in oncogenesis. The ErbB2/ErbB3 heterodimer has been shown to 30 promote efficient activation of the PI3K pathway, a pathway essential for cell proliferation and survival. However, other kinases implicated in tumorigenesis such as Src and Erk are

and the second second the second 
and the control of th

validated drug target.

n de Zerone (not le 1964) en 2011 de la combacción de la calegação de la combacción de la combacción de la comb

an tarah di kabupatèn kacamatan kabupat kabupatèn kabupatèn kabupatèn kabupatèn kabupatèn kabupatèn kabupatèn

COMPANIE AND DESCRIPTION OF THE SECOND STATES AND SECOND SECOND

- CO 44.7 C.... 2900年 1944 さつ (ASSA) 7月17日 20

also activated downstream of this ErbB heterodimer. Although downstream targets of
ErbB signaling have been characterized, the crucial molecular players with regard to Neuinduced transformation, specifically transcription factors that execute the signals received,
remain elusive.

The ability to detect tumors or a likelihood or predisposition of development of a tumor would be of great benefit in terms of patient care and initiating anti-tumor therapy at an early stage.

- 10 The regulation of the FoxO subgroup of forkhead transcription factors, consisting of forkhead (FKH) transcription factors R (FKHR), RL1 (FkHRL1) and AFX has been recently identified as being via the PI3K pathway. These proteins drive the expression of cell cycle regulators, such as p27 and apoptotic proteins including Bim and Fas ligand.

  Phosphorylation on specific serine and threonine residues by phosphokinase B (PKB) leads
- 15 to their inactivation and sequestration in the cytoplasm by 14-3-3 scaffolding proteins,
  thereby preventing their negative control on cell proliferation.

In accordance with the present invention, a novel 35kD phosphoprotein has been identified

which is specifically recognized by a phospho-FKHR antibody. It is proposed that the

20 novel protein is a useful diagnostic and prognostic target for cancer as well as being a

Marko Marko (1918) - And Harris and State of the Artist of the Committee o

recommendation of the control of the

PART BEFORE HARROWS IN A CAR A STATE

THE WAY OF THE STEEL WINDOWS TO SEE THE STEEL OF THE STEEL OF THE SECOND STEEL OF THE SECOND STEEL OF THE SECOND S

PROPERTY OF A MOST OF A CONTRACTOR AND A STATE OF A STA

-4-

30-508 AMERICAN AND THE RESERVE OF THE SECOND S

### SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the 5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. 

Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1 10 (SEQ ID NO:1), <400>2 (SEQ ID NO:2), etc. A summary of the sequence identifiers is provided in Table 1. A sequence listing is provided at the end of the specification.

tina an en man, al la servició de la comencia de l

The aberrant expression of the ErbB2 (also known as HER2 and Neu) receptor tyrosine kinase, implicated in the pathogenesis of a high proportion of sporadic breast cancers, was 15 investigated. Targeted expression of ErbB2 to the mammary gland in mice leads to tumor development. A long latency period, however, suggested that additional molecular alterations were acquired during the transformation process. A novel phosphoprotein, referred to herein as "FORS" (Forkhead Related Serine) was identified as being upregulated at the mRNA level in Neu tumors and in human breast carcinoma cell lines. The 20 gene (including cDNA) encoding FORS is referred to herein as "Fors".

It is proposed, in accordance with the present invention, that alterations in the FORS protein, the Fors gene of the expression of the Fors gene facilitates development of or otherwise predisposes a subject to, the development of a tumor and in particular a **25** plining 4, 201 mammary tumor. The term "tumor" includes all forms of cancer including sarcomas and carcinomas. The present invention further relates to the treatment or prophylaxis of a tumor and in particular breast cancer by the application of genetic therapy or the \*\*\* Association of proteinaceous or non-proteinaceous molecules which mimic or otherwise obviate the need for or otherwise act as agonists of Fors or FORS. Furthermore, Fors or FORS or derivatives or homologs thereof, may be employed to screen for potential therapeutic agents such as from natural sources or chemical or peptide libraries.

te a september a la servició de la companya de la c

Propertia psychologici sychilitris propine 1912/07.

It is further proposed, therefore, that Fors or FORS represents a validated drug target for modulators of Fors expression or FORS activity.

5. Another aspects of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence of Fors. Reference to "Fors" include genomic and cDNA molecules. Such nucleic acid molecules may be useful in genetic therapy to Waster Charles modulate expression of genomic Fors and/or recombinant FORS and, in particular, to Books in any n reduce or otherwise ameliorate production of FORS.

ot az legiona 10 egy, chila koza escencia da mareja, az betek A**liki kaszeris kozaso** kozeta a elektrik kozas <mark>bila</mark>

ra galerija

The present invention further provides methods of diagnosis of a tumor, and in particular a breast cancer, by detecting presence or levels of FORS and/or mutations therein, or aberrations in one or both alleles of the Fors gene, or in the expression of one or both gene alleles. The present invention provides, therefore, diagnostic agents such as primers or 15 probes of the Fors gene or mutated portions thereof. The diagnostic agents of the present invention extend to immunointeractive molecules and in particular antibodies to all or antigenic parts of FORS. Such diagnostic agents are useful in the detection of a tumor or a predisposition for development of a tumor and in particular breast cancer.

n militar proprieta de la proposición de la como construir de la como construir de la como construir de la como

t experiencial experiencial experiencial for the control of the co

and the second of the second of the second process of the second of the

·西西山 (西京) (2) 医水流、黄色 (2) (4) 日本) (4) 森林 美數 (4) (2) (4) (4) (4) (4) (4) (4) (4)

militaria <u>a la marca de la compania del compania del compania de la compania del compania del compania de la compania de la compania de la compania del compa</u>

We have the later and the segment of the property of the later

HE CONTRACTOR IN A SECUL HER RESERVED A SECUL

TREPRESENTATION OF THE ANGLE OF THE PROPERTY OF THE CONTRACT OF THE PROPERTY O

The Market of the Market Addition of the Contract of the Contr

本国 1997年,秦国为5次6个元章 中经80年,《金属**38**0000元首为1101年,《安康·马克克克

to de la vivila de la compaña de la comp

ser mineral montre en la trongrama a la composition de la composit

anis est eigen transportunitation er eigen er e

an dissipat Hopera

The Law Means (Co.



Figure 1 is a representation of polyacrylamide gel electrophoresis (PAGE) showing that a tumor-specific 35 kD protein cross-reacts with a phospho-FKHR antibody. (A) Mammary tumors (T) and corresponding adjacent tissue (AT) or normal mammary gland tissue (NT) from B17, C13 and B14 MMTV-New transgenic female were dissected, protein lysates were prepared and separated by SDS PAGE. The gel was blotted and probed with phospho-FKHR specific antibody. After stripping, the gel was re-probed with (B) ErbB2and (C) tubulin-specific antibodies. Lysate from insulin-stimulated 293T cells, transiently transfected with a FKHR expression construct, was loaded as a positive control.

manifer over and a commence of the consideration of the consisting of the field of the consistency of the co

Figure 2 presents diagrammatic representations showing the purification of the 35 kD protein from SKBR3 cytosol. SKBR3 cytosolic protein lysate was subjected to (A) free flow electrophoresis and (B) reverse phase HPLC as described in the Examples. The 15 fractions obtained were separated by SDS PAGE and analyzed by immunoblotting using phospho-FKHR specific antibody. In the case of RP-HPLC samples, two fractions were pooled (C) Coomassie stain of fractions containing the 35kD protein from SKBR3 cytosolic protein lysate separated by (i) FFE, (ii) RP HPLC and (iii) 10% w/v SDS PAGE. (D) Alignment of part of the sequence of Q9Y365 (SEQ ID NO:2; band #1 in (C)) with 20 part of the sequence of FKHR1 (SEQ ID NO:3) around serine 256 (underlined), using the Town or the Dialign software.

A PROCESSA DE SE SE ESTA PROCESSA A CONTRAR A LA PROCESSA A ARCHARICA DE CONTRAR A RECONSTRUCCION DE SE SE EST Figure 3 provides representations indicating that FORS is a phosphoprotein and that it is highly expressed in liver. (A) Amino acid sequence of the full-length Q9Y365 (SEQ ID 25 NO.6). Peptides identified by mass spectrometry are highlighted. Methionine 68, from which translation is initiated, is indicated In (B) and (C), 293T cells were transiently transfected with HA- or Flag-tagged Fors. (B) Lysates were prepared and separated by SDS PAGE and immunoblotted using phospho-FKHR specific antibody. SKBR3 protein lysate was loaded as a control. (C) FORS was immunoprecipitated with Flag antibody and 30 incubated without or with alkaline phosphatase (CIP) for 45 min at 37°C prior to separation by SDS PAGE. The gel was blotted and probed with phospho-FKHR-specific

e de la radio entre entre a la la estracación de la compactación de la compactación de la compactación de la c

ting the company of the company server with the company of the com

antibody and re-probed with Flag specific antibody. 293T whole cell extract (WCE)

containing transfected Flag FORS was loaded as a control. (D) A commercially available

membrane (Clontech) containing poly(A)<sup>†</sup> RNA from different human tissues was

hybridized with a Fors cDNA probe.

68. Corroll (1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 -


Figure 4 provides representations of Northern analysis showing over-expression of Fors in breast and colon carcinoma cell lines. (A) Poly(A)<sup>+</sup> RNA from breast epithelial and (B) 20 µg total RNA from colon carcinoma cell lines were hybridized with FORS and ErbB2 or EGFR cDNA probes, respectively. Equal loading was confirmed by hybridizing with a 10 GAPDH cDNA probe. Note than only 6 µg RNA was loaded in the case of SKBR3 cells.

Figure 5 presents diagrammatic representations showing FORS expression and localization using a highly specific purified peptide antibody. (A) Alignment of human Pctp (SEQ ID NO:7) and FORS (SEQ ID NO:5). The Start domain is shown in red; the peptide to which a FORS-specific antibody was raised to is highlighted in blue. In (B) and (C), protein lysates of cell lines or mouse liver, as indicated, were separated by SDS PAGE. Gels were immunoblotted with purified FORS-specific antibodies #419 and/or #420. In (C), membranes were re-probed with ErbB2, phospho-FKHR and tubulin specific antibodies. (D) Merged confocal microscopy images of MCF7 cells immunostained with 20 #420 FORS-specific antibody (green) and counterstained with DAPI (blue). The control panel shows staining with secondary FITC-conjugated antibody and DAPI alone.

Figure 6 provides representations indicating the growth properties of murine fibroblasts stably expressing FORS. (A) Protein lysates of NIH3T3 and HER14 cells infected with 25 pBabePuro and pBabeFors retroviral expression vectors, respectively, were separated by SDS PAGE and immunoblotted with Pctpl antibody. (B) 2000 cells per well (96 well plate) were plated on day 0 in duplicates in 10% v/v and 0.5% v/v serum. Cell growth was assayed by addition of MTS reagent and measurement of absorbance after 2 hours at 490 nm, as described in the Examples.

- PROPERTY OF THE PROPERTY OF A CONTROL OF THE PROPERTY OF THE

- Marcala Control (1998) and included the Control of the Control (1998) and Sales Control of the Artificial Control of the Con



Service of

Figure 7 shows photographic representation indicating anchorage independent growth of fibroblasts expressing FORS. (A) 50,000 NIH3T3 Puro and Fors cells, and (B) and (C) 2,000 HER14 Puro and Fors cells were plated with or without 10 ng/ml EGF in a 0:35% w/v top agar. Photographs were taken 4 weeks later after staining with NBT overnight at a 5 2-fold magnification in (A) and a 1.5 fold magnification in (B) and (C).

delenador. O tendo esta el la cario de la cario de la cario de la cario de la cario del transferio de la la cario de  cario de la cario de la cario de la cario del cario de la cario della cario de la cario de la cario della cario della cario de la cario de la cario della cario dell

And the second of the second o

rdamente propo, este perferenciarea la referenciaria del mandre con este en el construcción de construcción de

A ST. TOUR PROLUMENT SPECIAL STATE

Contraction of the authority contracts the following special property of the second

THE REPORT OF THE PARTY AND ADMINISTRATION OF THE PARTY OF THE PARTY AND ADMINISTRATION OF THE PARTY ADMINISTRATION OF THE PARTY AND ADMINISTRATION OF THE PARTY ADMINISTRATION OF THE PARTY ADMINISTRATION OF THE PARTY AND ADMINISTRATION OF THE PARTY AND A

PRODUCTION OF THE PROPERTY OF

这点的要求通道的通过的转换的通知者。因为\$P\$大学的主题。如果我们的自己的一种多种的\$P\$\$P\$大概,这个目的自己的主要不是一个人<sub>的是</sub>,

and a second with the second and include the second of the contract and a second of the second of th

TO A SERVICE SERVICE TO A SERVICE OF THE

n ki Arassa na hazar Tena a ki bila

DATE OF THE PROPERTY OF THE PARTY OF THE PAR

185

and the Alliania are recognized in the Health

TRANSPORT REPORT OF A SERVICE OF THE PROPERTY 
Committee of the commit

The State of the S

THE RESERVE HE WAS A DOWN TO THE RESTRICT OF T

A Charles The 1995 North American Street Street Street

Trade to the trade of the state 
Simble Section (Section 1) Section (Section 1) Section (Section 1)

THE RESERVE OF THE PARTY OF THE SECOND SECON

and the Administration of the South Committee and the South Committee of the South Committe

The transfer for the same of the same and the same of 
CONTRACT BUT THE POST OF THE SECOND WITH SECOND SEC

· 特别的基础。这个人的一个人的一个人的一个人的



#### A summary of sequence identifiers used throughout the subject specification is provided in Table 1.

P-PO-per Vid. pro-in/COOX1188667 with Sect provides-13/12/02.

29.2 (Annual Control of Control o

## TABLE 1

## Summary of sequence identifiers

k Wester in the Cotte of the common of the common in the common the Common has predicted as the common the common of the common in the common of the common

- W.S.F.A.P. Strong B <mark>yan, m. 186</mark> 2243	gi. Alabayaa ila la la la la	an anno 1940 a tha ann an a
SEQUENCE	NAME	DESCRIPTION
TDNO.		A CONTROL OF THE PROPERTY OF T
1 1	1 FORS 265-	partial amino acid sequence of the FORS
- Marie Meren Williams	277	phosphoprotein (ESAVAESREERMG)
2	- 00V365	partial amino acid sequence of a predicted human
- Austries (1.20 - 1.200) William St.	-340 99	protein based on a comparative screen of the C. elegans
· · · · · · · · · · · · · · · · · · ·		proteome (QHADSLENIDESAVAESR) <sup>1</sup>
The contract Research to the Contract C	FKHR1	partial amino acid sequence of the transcription factor,
No article of the second of the second of the		FKHR (RRAASMDNNSKFAKSRSR) <sup>1</sup>
\$200 100 300 to 100 100 100 100 100 100 100 100 100 10	Fors	full-length cDNA encoding the FORS phosphoprotein
1888 - 1884 - 1884 - 1884 - 1885 - 1885 - 1885 - 1885 - 1885 - 1885 - 1885 - 1885 - 1885 - 1885 - 1885 - 1885	FORS	full-length amino acid sequence of FORS
	<b>]</b> .	phosphoprotein
6	full Q9Y365	full-length amino acid sequence of predicted human
		protein Q9Y365
i Alexandro de la	PCTP	full-length amino acid sequence of human phosphatidyl-
و المسابق المسابق المام والمحادث والم والمحادث والمحادث والمحادث والمحادث والمحادث والمحادث والمحادث و		choline transfer protein PCTP
- was in the Konstanting of	নাম । ভাৰতি সংক্ৰম (ক্ৰিকা), ক্ৰ	

BOOK CONTROL OF BUILDING AND THE CONTROL OF THE PARTICLE OF SERVICES AND ASSESSED TO THE SERVICES OF THE SERVICES AND ASSESSED ASSESSED.

a de montro de contrata de la compación de la c

roku traj provincije in pastek po provincije prakas markima aktorio provincije politika paste politika (kaj koj

ana ting ing ang aktive pangan ing ting pan<mark>ggapananggapanan</mark> ng panggapanggapan panggapan panggapanggapang pang

alended Nichel in de de ante de la recentration de la completade en entre de la completación de la completación

数据的设施设计,所谓证明,1915年1917年1918年,1916年1918年,1918年,1918年,1918年,1918年,1918年,1918年,1918年,1918年,1918年,1918年,1918年,1918年 1918年 - 
n di unitarakat<u>ikati 1</u>

1800 (n. 1902) bilancia (n. 1904) bilancia del del propositio (n. 1919) de la companie del la companie de la co

。1771年 新山港 网络多克·塞雷尔特勒克尔克尔克·威德尔克尔克尔克尔克尔克克尔克克尔克

The second of th

single amino acid code (see Table 2 for definitions)

Brown or a transfer

BUT THE PROPERTY OF THE PROPER

## 

。 1975年後月開発組織的1975年的日本政策、開展大阪会社会会社会会社会、198<mark>8年</mark>後の

#### Single and three letter abbreviations used throughout the specification are defined below.

P-OpenEIA prinsQ00202599867 webi. fore provides-1912/02

#### TABLE 2

# Single and three letter amino acid abbreviations

<b>5</b> . (1996)	Til San Kalifater en berede i 1994		
ti adelle Secretaria (c. te <mark>pe</mark>	AMINO ACID	THREE-LETTER ABBREVIATION	ONE-LETTER SYMBOL
British sanking a ta	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
	Aspartic acid	Asp	D. S.
	Cysteme	Cyś na krawia	
kalika sia kenji nebi		Gln	de er ek <b>g</b> ûrk kome dit e en û
	Glutamic acid	Glu	<b>E</b>
inaman ana aka <u>iz</u>	Glycine	Gly	G
alidaren la asser researe	Histidine	His	H
	Isoleucine	Ile de la companya de	Market Control
	Deucine se de la	Little d. to a Leuwer was a second	Section of the House of the Section
isi saka sam	Lysine	Lys	K.
earth mass made in the age	Methionine	Met	M F
Registration of the second	Phenylalanine Proline	Phe Pro	F
संबंधकारिका, १८३२ का <mark>विक</mark>	Serine	PTO Service Services	
   2014   Fully 2 機能を到する	Threonine	Thr.	T
	Tryptophan		W
	Tyrosine	Trp Tyr	
rich nam appreting <u>sin</u>	Valine	Val	
· <sup>18</sup> · COMPAND	Sec. of the Children Control	Xaa	
Maria de la compania	an charming page and		

which is the minimum assumed a

PrOperEID provid2007235985(,Web), Beriupsty don-11/12/02

### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides encoding a tumorigenesis-related phosphoprotein. The gene of the present 5 invention is referred to herein as "Fors". The tumorigenesis-related proteinaceous expression product of Fors is referred to herein as FORS. The expression product may, however, also include RNA (including spliced introns and exons) and an mRNA transcript and these are encompassed by the term "Fors". This term includes a gene or a cDNA molecule. A proteinaceous product includes a polypeptide comprising two or more amino 10 acid residues. A "polypeptide" in this context includes a protein or peptide. The present invention provides isolated nucleic acid molecules corresponding to Fors as well as nucleic acid primers and probes useful for detecting Fors, aberrations in the Fors gene including deletions, insertions, additions and point mutations as well as gene silencing di#doctex∰) events. The present invention further provides a means for detecting Fors expression 15 products including polypeptides and fragments thereof. The present invention further provides genetically modified animals having one or both alleles of Fors or its homolog deleted, mutated or its/their expression silenced. The present invention further provides genetically modified animals comprising Fors genes introduced or deleted. Such animals are useful animal models for testing the pathogenesis of cancer and/or for testing potential 20 anti-cancer agents: A consequence of the consequ

Accordingly, one aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding the amino acid sequence set forth in SEQ ID NO:5 or SEQ ID NO:6 or an amino acid sequence having at least about 40% similarity to SEQ ID NO:5 or SEQ ID NO:6 after optimal alignment.

As stated above, SEQ ID NO:5 represents a polypeptide expression product of *Fors* and is included in the term "FORS". SEQ ID NO:6 represents the amino acid sequence of a 30 predicted human protein, based on comparative screen of the *C. elegans* proteome with human EST nucleotide databases, designated herein "full Q9Y365".

an en sambrin mengenakan daran militir kalan mengenakan dan kempangan perpenakan dan kempangan berangan berang

PNOptnEjb.provt00021589457,wtbl.fora.prov.doc/13/12/03

FORS is proposed, in accordance with the present invention, to be a tumorigenesis-related phosphoprotein that is over-expressed in mouse mammary tumor cells and in human breast carcinoma cell lines, and is furthermore shown herein to co-operate with the ErbB/HER2 receptor in facilitating cellular transformation. The isolated nucleic acid molecule encoding the tumorigenesis-related phosphoprotein FORS is referred to herein as Fors. As stated above, the term "Fors" includes a genomic gene, a cDNA molecule and an mRNA transcript. 

eri.

7860000

55 C 1880

In a more particular aspect of the present invention, there is provided an isolated nucleic \*\*\* 10 s acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a polypeptide capable of facilitating, increasing or otherwise promoting the development of a tumor in a vertebrate animal, said polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:5 or SEQ ID NO:6 or an amino acid sequence having at least about 40% similarity to SEQ ID NO:5 or SEQ ID NO:6 after optimal Bolegia, delegia 15. agalignment. grang agang agang agang kepadahan dan kepada dalah dalah dalah kepada dalah kepada

on the second of the text of the second second second second text of the second As stated above, the isolated nucleic acid molecule is referred to herein as Fors: 

Consequently, an even more particular aspect of the present invention contemplates an 20 sisolated nucleic acid molecule comprising a nucleotide sequence or a complementary nucleotide sequence having the identifying characteristics of Fors including a nucleotide sequence substantially as set forth in SEQ ID NO:4 or a part or fragment thereof or a nucleotide sequence having at least about 40% similarity to SEQ ID NO:4 after optimal alignment or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 its 25 - complementary form under low stringency conditions.

Reference to "Fors" includes a genomic DNA, cDNA or mRNA sequence comprising an open reading frame or a genomic nucleotide sequence comprising exons and optionally Signatura de la <mark>introns</mark>tratificada de la composición del composición de la composición de la composición de la composición del composición de la composición de la composición del composición de la composición de la composición de la composición del composición del composición de la composición del composición del composición del composición del composición del composi

renter to the common that the common the common of the common of the common the common and the common of the commo

Howard Man in the deal of a factory of the control of the aggregation and the control of the c

Reference herein to "Fors" includes derivatives or homologs thereof. A derivative includes

THE REPORT OF THE PARTY OF THE

a mutant, part, fragment or portion of Fors as well as any fusion derivatives such as formed by the fusion of one or more nucleotide sequences to the 5' or 3' terminal portion of Fors or to the 5' or 3' terminal portion of a fragment of Fors such as an intron or exon fragment. A derivative of Fors includes single or multiple nucleotide substitutions, additions and/or deletions or inversions to all or part of Fors and also includes point mutations and cross-over events. The term "Fors" also includes its 5' and 3' untranslated regions including a promoter operably linked to Fors or a heterologous gene. 

The present invention provides, therefore, an isolated nucleic acid molecule capable of 10 directing transcription of a second nucleic acid molecule operably linked to the first mentioned nucleic acid molecule wherein said first nucleic acid molecule comprises a nucleotide sequence which is 5' of a nucleotide sequence set forth in SEQ ID NO:4 or a nucleotide sequence having at least about 40% similarity to SEQ ID NO.4 after optimal alignment or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 or its 15 complement under low stringency conditions.

In this embodiment, the first mentioned nucleic acid molecule is referred to herein as the Fors promoter. The Fors promoter may be used to direct expression of Fors or of a heterologous gene or cDNA molecule.

0 40 1875 (1. 10 **20** 20 60 0 21 17 (1. 2000), 1996 (1877 (1. 2000) 260 (1. 2000) (1. The Fors gene may be from an animal cell including from a mammal, insect, reptile, fish, avian species, arachnid or lower order organism such as a yeast, fungus or C. elegans. Most preferably, the Fors gene is from a mammal such as a human or other primate, livestock animal (e.g. sheep, pig, cow, donkey, horse, goat), laboratory test animal (e.g. 25 mouse, rat, rabbit, hamster, guinea pig), a companion animal (e.g. dog, cat) or a captive wild animal. Most preferably, the Fors gene is from a human or mouse. The control of the second section of the control of

The exemplified Fors nucleotide sequence is of human origin and more particularly for human breast carcinoma cell line SKBR3 available from ATCC under Catalogue No. HTB30. Reference herein to "Fors" includes reference to the human forms of the gene as well as homologs from other species such as C. elegans as well as a range of West of the Control o

The first of the first had the first of the

建氯化铁 机铁头 医外性海炎 电流通讯器

A CARLO TOTAL SECTION OF THE SECTION OF

polymorphic variants and/or splice variants.

nas ciss *kernin<mark>ahindakan kerak</mark>an*an manjak (1868-1864) inta kerakan

The term "gene" is used in its broadest sense and includes cDNA corresponding to the exons of a gene. Accordingly, reference herein to a "gene" is to be taken to include:-

(i) a classical genomic gene consisting of transcriptional and/or translational regulatory sequences and/or a coding region and/or non-translated sequences (i.e. introns, 5'- and 3'- untranslated sequences); or

i i Kwalisa.

210 (ii) mRNA or cDNA corresponding to the coding regions (i.e. exons) and 5'- and 3'untranslated sequences of the gene.

The term "gene" is also used to describe synthetic or fusion molecules encoding all or part of an expression product. In particular embodiments, the term "nucleic acid molecule" and 15 "gene" may be used interchangeably. The term "polynucleotide" may also be used to describe a nucleic acid molecule, nucleotide sequence and a gene

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level. 20 "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, 25 nucleotide and sequence comparisons are made at the level of identity rather than 

Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence", "comparison window", "sequence similarity", 30 "sequence identity", "percentage of sequence similarity", "percentage of sequence identity", "substantially similar" and "substantial identity". A "reference sequence" is at

least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units. inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of más áta sz sequence similarity. A "comparison window" refers to a conceptual segment of typically 12 configuous residues that is compared to a reference sequence. The comparison window 10 may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerised implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics 15 Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as, for example, disclosed by Altschul et al. (Nucl. Acids Res. 25: 3389, 1997). A detailed discussion of sequence analysis can be found in Unit 19.3 of 20. Ausubel et al. ("Current Protocols in Molecular Biology" John Wiley & Sons Inc, 1994-

The terms "sequence similarity" and "sequence identity" as used herein refer to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison.

Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g. A, T, C, G, I) or the identical amino acid residue (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the

Barrellian Track to the west with the

window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering 5 Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity. 

1975 A 120 JOSEPH . . . Preferably, the percentage similarity between a particular sequence and a reference 10 sequence (nucleotide or amino acid) is at least about 50% or at least about 60% or at least about 70% or at least about 80% or at least about 90% or at least about 95% or above such as at least about 96%, 97%, 98%, 99% or greater. A na Patricia di Patricia.

24 70 Pro 1988 18

V 6.00 PAC **15.** 

Reference herein to a low stringency includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions. Generally, low stringency is at from about 25-30°C to about 42°C. The temperature may be altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions. Alternative stringency conditions may be applied where necessary, 20 such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 25 0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions. In general, washing is carried out  $T_m = 69.3 + 0.41$  (G+C)% (Marmur and Doty, J. Mol. Biol. 5: 109, 1962). However, the Tm of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatch base pairs (Bonner and Laskey, Eur. J. Biochem. 46: 83, 1974). Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC

buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x SSC buffer, 0.1% w/v SDS at a temperature of at least 65°C.

A "Fors allele" refers to normal alleles of the Fors locus as well as alleles carrying

5 variations that may modulate an individual's predisposition to the development of a tumor and, in particular, a mammary tumour.

The terms "nucleic acids", "nucleotide" and "polynucleotide" include RNA, cDNA genomic DNA, synthetic forms and mixed polymers, both sense and antisense strands, and 10 may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g. methyl phosphonates, phosphotriesters, phosphoamidates, 15 carbamates, etc.), charged linkages (e.g. phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g. polypeptides), intercalators (e.g. acridine, psoralen, etc.), chelators, alkylators and modified linkages (e.g. o-anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen binding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for The reference of the second phosphate linkages in the backbone of the molecule. To difference in this second commence which is the commence of the commence of the commence of the commence of

The present invention further provides recombinant nucleic acids including a recombinant construct comprising all or part of the Fors coding and/or regulatory region. The 25 recombinant construct may be capable of replicating autonomously in a host cell.

Alternatively, the recombinant construct may become integrated into the chromosonal DNA of the host cell. Such a recombinant polynucleotide comprises a polynucleotide of genomic, cDNA, semi-synthetic or synthetic origin which, by virtue of its origin or manipulation: (i) is not associated with all or a portion of a polynucleotide with which it is 30 associated in nature; (ii) is linked to a polynucleotide other than that to which it is linked in nature; or (iii) does not occur in nature. Where nucleic acids according to the invention

CAND TO THE REPORT OF THE SECOND TO A CONTROL OF THE CONTROL OF THE SECOND TO SECOND THE 
include RNA, reference to the sequence shown should be construed as reference to the RNA equivalent with U substituted for T.

Therefore, recombinant nucleic acids comprising sequences otherwise not naturally

5 occurring are provided by the present invention. Although the wild-type sequence may be employed, it will often be altered, e.g. by deletion, substitution or insertion.

cDNA or genomic libraries of various types may be screened as natural sources of the nucleic acids of the present invention or such nucleic acids may be provided by amplification of sequences resident in genomic DNA or other natural sources, e.g. by PCR.

The choice of cDNA libraries normally corresponds to a tissue source, which is abundant in mRNA for the desired protein. Phage libraries are normally preferred but other types of libraries may be used. Clones of a library are spread onto plates, transferred to a substrate for screening, denatured and probed for the presence of desired sequences.

As used herein, the terms "Fors locus" and "Fors allele" refer to the double-stranded DNA comprising the locus, allele or region, as well as either of the single-stranded DNAs comprising the locus, allele or region.

As used herein, a "portion or part or fragment" of the Fors locus or allele is defined as having a minimal size of at least about 10 nucleotides or preferably about 13 nucleotides or more preferably at least about 20 nucleotides and may have a minimal size of at least about 40 nucleotides. This definition includes all sizes in the range of 10-40 nucleotides as well as greater than 40 nucleotides. Thus, this definition includes nucleic acids of 12, 15, 20, 25, 25, 40, 60, 80, 100, 200, 300, 400, 500 or 700 nucleotides or nucleic acids having any number of nucleotides within these values (e.g. 13, 16, 23, 30, 38, 50, 72, 121, 673 etc. nucleotides) or nucleic acids having more than 700 nucleotides or any number of

nucleotides) or nucleic acids having more than 700 nucleotides or any number of nucleotides between 700 and the number shown in SEQ ID NO:4. The present invention includes all novel nucleic acids having at least 10 nucleotides derived from SEQ ID NO:4.

LOUNT TO THE SECTION OF THE SECTION

30 or a complement or functional equivalent thereof.

人物,可以自己的 人名英格兰人姓氏

Property of the property of the same

"Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter effects its transcription or expression.

Large amounts of the polynucleotides of the present invention may be produced by replication in a suitable host cell. Natural or synthetic polynucleotide fragments coding for a desired fragment will be incorporated into recombinant polynucleotide constructs; usually DNA constructs, capable of introduction into and replication in a prokaryotic or 10 eukaryotic cell. Usually, the polynucleotide constructs are suitable for replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to (with or without integration within the genome) cultured mammalian or plant or other eukaryotic cell lines. The purification of nucleic acids produced by the methods of the present invention are described, e.g. in Sambrook et al. (Molecular Cloning: A Laboratory 15 Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).

The polynucleotides of the present invention may also be produced by chemical synthesis,
e.g. by the phosphoramidite method described by Beaucage and Carruthers (*Tetra. Letts.*22: 1859-1862, 1981) or the triester method according to Matteucci et al. (*J. Am. Chem.*20. Soc. 103: 3185, 1981) and may be performed on commercial, automated oligonucleotide synthesizers. A double-stranded fragment may be obtained from the single-stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strands together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

The control of the co

Polynucleotide constructs prepared for introduction into a prokaryotic or eukaryotic host may comprise a replication system recognized by the host, including the intended polynucleotide fragment encoding the desired polypeptide and will preferably also include transcription and translational initiation regulatory sequences operably linked to the polypeptide encoding segment. Expression vectors may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences,

and the material leaves of the contraction of the c

100

6-82-80a

હુટું જયાં

See: 7

But State of the S

a promoter, an enhancer and necessary processing information sites, such as ribosomebinding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences and mRNA stabilizing sequences. Secretion signals may also be included, where #Walifakurabaji appropriate, which allow the protein to cross and/or lodge in cell membranes or be secreted 5 from the cell. Such vectors may be prepared by means of standard recombinant techniques well known in the art and discussed, for example, in Sambrook et al. (1989) supra.

An appropriate promoter and other necessary vector sequences is selected so as to be functional in the host and may include, when appropriate, those naturally associated with 10 Fors genes Examples of workable combinations of cell lines and expression vectors are described in Sambrook et al. (1989) supra). Many useful vectors are known in the art and may be obtained from suppliers such as Stratagene, New England Biolabs, Promega 10400000000000 Biotech and others. Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts. Useful yeast promoters 15 include promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization and others. Vectors and promoters suitable for use in yeast expression are further described in European Patent Publication No. 0 073 675 Appropriate non-native mammalian promoters might include 20 the early and late promoters from SV40 (Fiers et al., Nature 273: 113-120, 1978) or promoters derived from murine mammary tumor virus (MMTV), mouse tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. Insect promoters may be derived from baculovirus. In addition, the construct may be joined to an amplifiable gene (e.g. DHFR) so that multiple copies of the gene may be made. For appropriate 25 enhancer and other expression control sequences, see also Enhancers and Eukaryotic Gene Expression, Cold Spring Harbor Press, Cold Spring Harbour, New York (1983). See also, han iki baharawa merendah e.g. U.S. Patent No. 5,691,198. 

While such expression vectors may replicate autonomously, they may also replicate by 30 being inserted into the genome of the host cell, by methods well known in the art.

Proposition of the contract of

Expression and cloning vectors will likely contain a selectable marker and a gene encoding a protein necessary for survival or growth of a host cell transformed with the vector. The presence of this gene ensures growth of those host cells that express the inserts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxic 5 substances, e.g. ampicillin, neomycin, methotrexate, etc., (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the <del>Salahar Andria K</del>arata Ada gene encoding D-alanine racemase for Bacillus. The choice of the proper selectable marker will depend on the host cell and appropriate markers for different hosts are well known in På) avil Herbuses the art. 

The vectors containing the nucleic acids of interest can be transcribed in vitro and the resulting RNA introduced into the host cell by well-known methods, e.g. by injection (see Kubo et al., FEBS Lett. 241: 119, 1988), or the vectors can be introduced directly into host cells by methods well known in the art, which vary depending on the type of cellular host, 15 including electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome); and other methods. See generally, Sambrook et al. (1989) supra. The introduction of the polynucleotides into the host cell by any method known in the art, including, inter alia, 20 those described above, will be referred to herein as "transfection". The cells into which have been introduced nucleic acids described above are meant to also include the progeny of such cells.

Large quantities of the nucleic acids and polypeptides (see below) of the present invention 25 may be prepared by expressing the Fors nucleic acids or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of E. coli, although other prokaryotes, such as Bacillus subtilis or Pseudomonas may also be used.

Mammalian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant, insect or amphibian or avian species, may also be useful for production of the proteins of 

to a language of the companies of the companies of the contraction of

iiwo wa o

the present invention. Propagation of mammalian cells in culture is per se well known. See Jakoby and Pastan (eds.), Cell Culture. Methods in Enzymology, Vol. 58, 1979 (Academic Press, Inc., Harcour Brace Jovanovich (New York). Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, 5 293T and NIH3T3 cell lines, and WI38, BHK, and COS cell lines. An example of a commonly used insect cell line is SF9. However, it will be appreciated by the skilled practitioner that other cell lines may be appropriate, e.g. to provide higher expression, desirable glycosylation patterns or other features. teritationis, alterit emines. Elementes en l'angere de l'internation, l'inflatant de la completation de les companies de la

10 Clones are selected by using markers depending on the mode of the vector construction. The marker may be on the same or a different DNA molecule, preferably the same DNA molecule. In prokaryotic hosts, the transformant may be selected, e.g. by resistance to ampicillin, tetracycline or other antibiotics. Production of a particular product based on temperature sensitivity may also serve as an appropriate marker.

Prokaryotic or eukaryotic cells transformed with the polynucleotides of the present invention are useful not only for the production of the nucleic acids and polypeptides of the present invention but also, for example, in studying the characteristics of a FORS polypeptide. A second control of the 
Antisense polynucleotide sequences are particularly useful in the context of the present invention as they may prevent or diminish the expression of the Fors locus and, as will be appreciated by those skilled in the art, this may effect reduction or elimination of expression products from Fors, including Fors mRNA and FORS. Since FORS is over-25 expressed in breast cancer cell lines and in mammary tumors, and is associated with the undesirable changes concomitant with cellular transformation and the development of uncontrolled proliferation, the means to ameliorate or diminish FORS may have beneficial therapeutic potential. Polynucleotide vectors, for example, containing all or a portion of the Fors locus or other sequences from the Fors region (particularly those flanking the Fors locus) may be placed under the control of a promoter in an antisense orientation and introduced into a cell. Expression of such an antisense construct within a cell interferes Con. Expression of Such Control of the State 
The 18th West War days in the deep

the control of the co

i şibəy ə

Alemania (1884) de 1886 de Maria de Maria Ma with Fors transcription and/or translation. Furthermore, alternative approaches to downregulation using sense constructs, such as co-suppression and mechanisms to induce RNAi, may also be employed.

> The present invention is particularly useful for screening compounds by using the FORS polypeptide or binding fragment thereof in any of a variety of drug screening techniques, such as those described herein and in International Publication No. WO 97/02048.

ikilan ning di Kabupatèn kalikan kampan bahin perangkilan Kabupatèn Kabupatèn Kilabahan kalikan kalikatèn kali

Yet another aspect of the present invention contemplates an expression product of Fors. The expression product may be a polypeptide encoded by the open reading frame of Fors (i.e. see SEQ ID NO:5 or SEQ ID NO:6) or it may be an mRNA or RNA molecule spliced from an mRNA or precursor form thereof. Such RNA molecules include exons and introns. Such molecules or their corresponding DNA sequences may be useful as regulatory molecules in their own right or as diagnostic probes or primers for detecting wild-type or a mutated or deleted Fors gene. AMORES TENTEEN VERLEET EN EN EEN EEN EEN EEN EEN EEN EKENDE EKKERTEN EEN EN EN EN EN EKKERTEN EEN EN EEN EN EKKERTEN.

Accordingly, another aspect of the present invention provides an expression product from Fors, said expression product selected from the list comprising

an amino acid sequence set forth in SEQ ID NO:5 or an amino acid sequence having at least 40% similarity to SEQ ID NO:5 after optimal alignment;

Part of the formation of the state of the contract of the first of the formation of the community of the contract of the contr

· Participae Alice · Alice Alice and Commercial Commercial Action in Action Commercial Action (Action Commercial Action 
TO SHE FROM SHOWING TO SHE

Mark Burns

ukawan ing kempangawan kwatawa pangangan pangangan di Sangabatan kanawan kanawa katawa katawa na pangan pangan

- (ii) an amino acid sequence set forth in SEQ ID NO:5;
- en bleverk om en erskilt med at er ken kommen med at flækk makke kinner fore en bleverk gjekke kenten blev bet an amino acid sequence set forth in SEQ ID NO:6 or an amino acid sequence having at least 40% similarity to SEQ ID NO:6 after optimal alignment;
  - (iv) an amino acid sequence set forth in SEQ ID NO:6;

AND SAME AND MINERAL SECTION OF A STATE OF A

a ribonucleotide sequence corresponding to SEQ ID NO:4 or a nucleotide TUDAST TUDASTA KANANDARIAN KANANDARIAN KANANDARIAN KANANDARIAN KANANDARIAN KANANDARIAN KANANDARIAN KANANDARIA sequence having at least about 40% similarity to SEQ ID NO:4 after optimal

alignment or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 or
its complementary form under low stringency conditions; and

## (vi) a ribonucleotide sequence corresponding to SEQ ID NO:4.

"FORS protein" or "FORS polypeptide" or specific FORS molecules from human or murine or other sources refers to a protein including a polypeptide encoded by the Fors TWE CALLS! locus, variants or fragments thereof. The term "polypeptide" refers to a polymer of amino acids and its equivalent and does not refer to a specific length of the product, thus, 20 peptides; oligopeptides; and proteins are included within the definition of a polypeptide. This term also does not refer to or exclude modifications of the polypeptide, for example, glycosylations, aceylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages as well as 15 other modifications known in the art, both naturally and non-naturally occurring. Ordinarily, such polypeptides will be at least about 40% similar to the natural FORS Berlinder Beldwicker sequence, preferably in excess of 50% such as greater than 60%, 70%, 80% or 90% and more preferably at least about 95% similar. Also included are proteins encoded by DNAs which hybridize under high or low stringency conditions to Fors-encoding nucleic acids 20 and closely related polypeptides or proteins retrieved by antisera to the FORS protein.

The FORS polypeptide is shown in SEQ ID NO:5 and SEQ ID NO:6 and may be in isolated and/or purified form, free or substantially free of material with which it is naturally associated. The polypeptide may, if produced by expression in a prokaryotic cell or produced synthetically, lack native post-translational processing, such as glycosylation.

Alternatively, the present invention is also directed to polypeptides which are sequence variants, alleles or derivatives of the FORS polypeptide. Such polypeptides may have an amino acid sequence which differs from that set forth in SEQ ID NO:5 or SEQ ID NO:6 by one or more of addition, substitution, deletion or insertion of one or more amino acids.

30 Conveniently, such polypeptides have FORS function but if not, they may nevertheless be useful in diagnostic or therapeutic assays.

Winds with Mark

No de la constitución de la contra

na zpravi sa tukom peteronogog je

ńŵte:

Sant Salay

in it is

Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein and may be designed to modulate one or more properties of the polypeptide such as stability against proteolytic cleavage without the loss of other 5 functions or properties. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. Preferred substitutions are ones that are conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and typically include substitutions within the following groups: 40 glycine, alanine; valine, isoleucine, leucine, aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and tyrosine, phenylalanine.

Certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, 15 antigen-binding regions of antibodies or binding sites on substrate molecules or binding sites on proteins interacting with the FORS polypeptide. Since it is the interactive capacity and nature of a protein which defines that protein's biological functional activity, certain amino acid substitutions can be made in a protein sequence and its underlying DNA coding sequence and nevertheless obtain a protein with like properties. In making such changes, 20 the hydropathic index of amino acids may be considered. The importance of the hydrophobic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, J. Mol. Biol. 157: 105-132, 1982). Alternatively, the substitution of like amino acids can be made effectively on the basis of hydrophilicity. The importance of hydrophilicity in conferring interactive biological 25 function of a protein is generally understood in the art (U.S. Patent No. 4,554,101). The use of the hydrophobic index or hydrophilicity in designing polypeptides is further and the first of the first of the state of t discussed in U.S. Patent No. 5,691,198. 要在京使等。但不够开始的,这个是一次一位的数据的数据的设备。2007年11月1日,以及这种产品的证明,但他们才被使

The length of the polypeptide sequences compared for homology will generally be at least 30 about 16 amino acids, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues and preferably more than about 35 residues. 

Albert of the first and a state of the state

The present invention further contemplates chemical analogs of the FORS polypeptide.

Analogs contemplated herein include but are not limited to modification to side chains,

5 incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide
or protein synthesis and the use of crosslinkers and other methods which impose
conformational constraints on the proteinaceous molecule or their analogues.

Examples of side chain modifications contemplated by the present invention include

10 modifications of amino groups such as by reductive alkylation by reaction with an
aldehyde followed by reduction with NaBH4; amidination with methylacetimidate;
acylation with acetic anhydride; carbamoylation of amino groups with cyanate;
trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS);
acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and

15 pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH4.

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

the state of the state of the state of

TO THE SERVICE WAS TRUBBLE TO

The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with

25 iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a

mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride

or other substituted maleimide; formation of mercurial derivatives using 4
chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2
chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline

pH.

war die Groek bij die die

Pidpettip providing 1 juint his grow doe 1 iv 12 abn.

Tryptophan residues may be modified by, for example, oxidation with bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative. Landina de Carreia

Modification of the imidazole ring of a histidine residue may be accomplished by Saranga Mesaksiyasi N-carbethoxylation with derivatives or iodoacetic acid alkylation ta sitalahidan kebatan dalah dalah biban bara dan berapah ing dibinak berapat diada kepada kerapat berapah ber diethylpyrocarbonate.

le Calum vers of the commission description. In the commission of the commission of the commission of the commission of the

1989 STOREST CONT

Tatab 1880. su**k** makabaka pakarat Pratisian Bara mendaka Barat dalah 1881 kada kendulak balan balah 1881 dalah 1881 kada barat dalah 18

10 Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated

tala disemberare di material anti all'arcolomisme, della salla di lacciona alle salla sella della colomba di l

TO A SHEET WAS A STREET

General Mesons and the Colonial American in the colonial for the

nan namangan kabupatèn kalawan nangan kan dipangan kalawan nangan balawan kabupatèn kanan kanan kanan kalawan k

are kontrol i entre relativitati i era in relativi karl terkhikatika kanan kisi terriri tenganka eta ketara arbitak 🖟 e

rainelles de rendeux du ser la Pusceria della Hangagian er er Konfelius kan da dan du demanderaja président de de de

stant dan memberakan menterberakan paraman bing mengerakan dan mententuk mengengan pada dan dan beratan beratan

return florier regional aggregation in the contract of the con

in transfer for the second of the contract of

ments of the 15% herein is shown in Table 3. The said the troof of the following solutions of the said said the

p. 第76 的复数视镜中枢系统转点的 八声:"常见其中的惊点,我**没**好的感染。"这些心理,但不是

P.Opat@it provid0072519867,webi fort prov.dos-11/12/02

### TABLE 3

# Codes for non-conventional amino acids

	The second of
5 Non-conventional Code	Non-conventional Code
amino acid	amino acid
α-aminobutyric acid Abu	L-N-methylalanine Nmala
The second of th	L-N-methylarginine Nmarg
10 α-amino-α-methylbutyrate Mgabu aminocyclopropane- Cpro	L-N-methylasparagine Nmasn
carboxylate	L-N-methylaspartic acid Nmasp
aminoisobutyric acid Aib	L-N-methylcysteine
Norb Norb	L-N-methylglutamine Nmgln
15 carboxylate	L-N-methylglutamic acid Nmglu
cyclohexylalanine Chexa	L-Nmethylhistidine Nmhis L-N-methylisolleucine Nmile
cyclopentylalanine Cpen D-alanine Dal	L-N-methylleucine Nmleu
A STATE OF THE PROPERTY OF THE	L-N-methyllysine Nmlys
20. D-aspartic acid Dasp	L-N-methylmethionine Nmmet
D-cysteine Dcys	L-N-methylnorleucine Nmnle
D-glutamine Dgln	L-N-methylnorvaline Nmnva
D-glutamic acid Dglu	L-N-methylomithine Nmorn
Diniskan Andrews Diniskan Andrews	LeNemethylphenylalanine Nmphe Nmphe
25 D-isoleucine Dile	L-N-methylproline Nmpro
D-leucine Dleu	L-N-methylserine Nmser
D-lysine Dlys	L-N-methylthreonine Nmthr
D-methionine Dmet	L-N-methyltryptophan
D-ornithine Dorn	IN-methyltyrosine Nmtyr
Dephe Dephe	L-N-methylvaline Nmval
D-proline Dpro	L-N-methylethylglycine Nmetg
D-serine Dser	L-N-methyl-t-butylglycine Nmtbug

٠..:

i	á
1	1

The Manager and the analysis of the second second second

### P:Oper(E)h piores100272189867.prehl first prov. 40e-13/12/02

D-threonine	Dthr	L-norleucine	Nle	2000
D-tryptophan	Dtrp	L-norvaline	Nva	85. TV6
D-tyrosine D-valine	Dtyr Dval	α-methyl-aminoisobutyrate α-methyl-γ-aminobutyrate	Maib Mgabu	
5 D-α-methylalanine	Dmala	α-methylcyclohexylalanine	Charles and a second second	diam'r.
D-α-methylarginine	Dmarg	• •	Mcpen	(sika
28.02.626 : Age D-α-methylasparagine	Dmasn	α-methyl-α-napthylalanine	Manap	
D-α-methylaspartate	Dmasp	α-methylpenicillamine	Mpen	G314
D-α-methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu	१८४१ <sup>ई</sup>
10 D-α-methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg	\$.15.pr
D-a-methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Nom	<b>.</b>
D-α-methylisoleucine	Dmile	N-amino-α-methylbutyrate	Nmaabu	erij.
D-α-methylleucine	Dmleu	α-napthylalanine	Anap	\$2.2
. D-α-methyllysine	<b>Dmlys</b>	N-benzylglycine	Nphe	
15 D-α-methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln	88.A
D-α-methylomithine	Dmorn	N-(carbamylmethyl)glycine	1	(q: g
D-a-methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	-Nglu	• **
D-or-methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp	, .r.
D-α-methylserine	Dmser	N-cyclobutylglycine	Nebut	1
20 D-α-methylthreonine	Dmthr	N-cycloheptylglycine	Nchep	in in
D-α-methyltryptophan D-α-methyltyrosine	Dmtrp	N-cyclohexylglycine	Nadaa	
D-α-methylvaline	Dmty Dmyal	N-cyclodecylglycine	Nedod	3 .
D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct	ā i
25 D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro	i.s
D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Neund	81-1
_ · · · · ·		N-(2,2-diphenylethyl)glycine		
D-N-methylcysteine				
D-N-methylglutamine			Narg	
30 D-N-methylglutamate		N-(1-hydroxyethyl)glycine	Nthr	েব •
		WENT OF THE REMAINS WITH THE PROPERTY.	in the interpretation of	

THE SPECIAL PLANSE WAS A PROPERTY OF



market for the state of the sta

Commence of the control of the state of the

# PrOperEn jeon/Coon/1587667 weblieft proc.doi:11/12/07

The second of the second secon

		The contract of the contract o	e i contrato de contrato de la contrato del contrato del contrato de la contrato del contrato del contrato de la contrato del contrato de la contrato del contrato del contrato del contrato del contrato de la contrato del
D-N-methylhistidine	Dnmhis	N-(hydroxyethyl))glycine	Nser
D-N-methylisoleucine	Dnmile	N-(imidazolylethyl))glycine	Nhis
D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl-γ-aminobutyrate	Nmgabu
5 N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Diminet
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
10 N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Drimthr
D-N-methyltryptophan	Dumtrp	N-(1-methylethyl)glyoine	Nval
D-N-methyltyrosine	Dnmtyr	N-methyla-napthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
γ-aminobutyric acid	Gabu	N-(p-hydroxyphenyl)glycine	Nhtyr
15 L-t-butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe A Co.	L-α-methylalanine	Mala
L-or-methylarginine	Marg	L-α-methylasparagine	Masn
L-α-methylaspartate	Masp	L-α-methyl-t-butylglycine	Mtbug
20 L-α-methylcysteine	Mcys	L-methylethylglycine	Metg
L-α-methylglutamine	Mgln	$L$ - $\alpha$ -methylglutamate	Mglu
L-α-methylhistidine	Mhis	L-α-methylhomophenylalanine	Mhphe
L-α-methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
L-α-methylleucine	Mleu	L-α-methyllysine	Mlys
25 L- $\alpha$ -methylmethionine  L- $\alpha$ -methylnorvaline  L- $\alpha$ -methylphenylalanine	Mmet	L-α-methylnorleucine	Mnle
$L$ - $\alpha$ -methylnorvaline	Mnva	L-α-methylornithine	Morn
• • • • • • • • • • • • • • • • • • • •	<b></b>		
L-a-methylserine	Mser	L-a-methylthreonine	Mthr
L-α-methyltryptophan	Mtrp	L-α-methyltyrosine	Mtyr
30 L-α-methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe
The second secon	1 - 19 - 1800 P - 15 15 15 15 15 15 15 15 15 15 15 15 15	\$1.00 & 1.00 (10 12.00 )	Mare de la Republica de la companya

THE WORLD STATE

\$6-0843 \$446-\$6 \$\$\$\$\$\$\$\$\$\$\$\$\$

N-(N-(2,2-diphenylethyl) Nnbhm N-(N-(3,3-diphenylpropyl) Nnbhe carbamylmethyl)glycine carbamylmethyl)glycine

1-carboxy-1-(2,2-diphenyl- Nmbc ethylamino)cyclopropane 

Crosslinkers can be used, for example, to stabilize 3D conformations, using homobifunctional crosslinkers such as the bifunctional imido esters having (CH<sub>2</sub>)<sub>n</sub> spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional 10 reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of  $C_{\alpha}$  and  $N_{\alpha}$ -methylamino acids, introduction of double bonds between C<sub>a</sub> and C<sub>b</sub> atoms of amino acids and the formation of cyclic peptides or analogues 15 by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

The term "peptide mimetic" or "mimetic" is intended to refer to a substance, which has the essential biological activity of the FORS polypeptide. A peptide mimetic may be a peptide-20 containing molecule that mimics elements of protein secondary structure (Johnson et al., "Peptide Turn Mimetics" in Biotechnology and Pharmacy, Pezzuto et al., Eds., Chapman and Hall, New York, 1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions such as those of antibody and antigen, enzyme 25 and substrate or scaffolding proteins. A peptide mimetic is designed to permit molecular interactions similar to the natural molecule. A mimetic may not be a peptide at all, but it will retain the essential biological activity of natural FORS polypeptide.

The FORS polypeptide or fragment employed in a test such as a diagnostic or therapeutic 30 assay may either be free in solution, affixed to a solid support, or borne on a cell surface. One method of drug screening utilizes eukaryotic or prokaryotic host cells that are stably

transformed with recombinant polynucleotides expressing the polypeptide or fragment, preferably in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between a FORS polypeptide or fragment and the agent being tested, or 5 examine the degree to which the formation of a complex between a FORS polypeptide or fragment and a known ligand is aided or interfered with by the agent being tested.

It is proposed in accordance with the present invention that tumors have a propensity to develop in subjects who have cells in which the Fors gene is expressed. Consequently, the 10 diagnostic and prognostic methods of the present invention detect or assess the presence of the Fors gene or locus and confirm the presence of a tumor or a predisposition to the development of a tumor. Useful diagnostic techniques to detect the presence of Fors include but are not limited to fluorescent in situ hybridization (FISH), direct DNA sequencing, PFGE analysis, Southern blot analysis, single-stranded conformational 15 analysis (SSCA). RNase protection assay, allele-specific oligonucleotide (ASO hybridization), dot blot analysis and single-stranded conformation polymorphism assay (SSCP) [Orita et al., Proc. Nat. Acad. Sci. USA 86: 2776-2770, 1989]. Also useful is DNA microchip technology as well as electrotide. Electrotides may also be used as a detection system. Such a system relies on complementary binding of RNA or DNA to assemble an 20 electronic circuit which thereby creates a detectable electronic signal. One particularly useful system is eSensor (trade mark; Motorola) which is well described http://www.motorola.com/lifesciences/ esensor/tech\_overview.html. THE SECTION OF THE SECTION OF THE PROPERTY OF

Predisposition to cancers, such as mammary tumors, can be ascertained by lesting any 125 tissue of a human for the presence of an expressible Fors gene. For example, an individual who has inherited a germ-line Fors gene would be prone to develop cancers. This can be determined by testing DNA from any tissue of an individual's body. In addition, pre-natal diagnosis can be accomplished by testing foetal cells, placental cells or amniotic fluid for the presence of the Fors gene.

san bir Disking

in axima bari da a

It should be pointed out that reference to a "subject", "individual", "patient" or "vertebrate

THE COURSE PARTY OF THE SPECIFICAL HERE SEED

animal" is not to be taken as limiting the target to a particular animal or human. The present invention is applicable to detecting tumors in a range of vertebrate animals, although humans are preferred. 

5 Alteration of Fors mRNA expression can be detected by any of a number of techniques known in the art. These include Northern blot analysis, PCR amplification, RNase protection and microchip technology. Diminished mRNA expression correlates with reduced levels of expressed FORS phosphoprotein and, consequently, increased likelihood e de la compania de of enhanced therapeutic outcomes. Analogously, enhanced mRNA expression correlates 10 with enhanced levels of expressed FORS phosphoprotein and, consequently, increased likelihood of the existence of or the propensity for the development of cancer and, in particular, mammary cancer. The need for intervention to deliver improved therapeutic outcomes is thereby indicated. 

有名词形 化氯化铁铁 医铁铁铁铁毛 医皮肤炎

- 15 Fors genes can also be detected by screening for a FORS protein. For example, monoclonal and polyclonal antibodies immunoreactive with FORS can be used to screen a tissue. Presence of cognate antigen indicates existence of FORS phosphoprotein and, hence, increased chance of the existence of or the propensity for the development of cancer and, especially, breast cancer. Such immunological assays can be done in any convenient format known in the art. These include Western blots, immunohistochemical assays and ELISA assays. Any means for detecting a FORS protein can be used to detect a wild-type Fors gene. And the second of the second o
  - The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production is derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation (i.e. comprising FORS) or can be done by techniques which are well known to those who are skilled in the art. (See, for example, Douillard and Hoffman, Basic Facts 30 about Hybridomas, in Compendium of Immunology Vol. II, ed. by Schwartz, 1981; Kohler

Not the Trial Walking

11. 78-53

\$\$\$\$1.500

\$2603########

sa sa Briga

27. s (Antonia) alianta sinta talla talla ana infanta sa kilolifaka, (1 a. s.) (1 a. s.) (1 a. s.) (1 a. s.) (1

Martine (

Bartak Bada kecamatan dari kalendari

in verification and a second

and Milstein, Nature 256: 495-499, 1975; Kohler and Milstein, European Journal of Immunology 6: 511-519, 1976). 

- Another aspect of the present invention contemplates a method for detecting EORS in a 5 biological sample from a subject, said method comprising contacting said biological sample with an antibody specific for FORS or its derivatives or homologs for a time and under conditions sufficient for an antibody-FORS complex to form, and then detecting said Flaggrege aggregation complex. Al provide come totale. Also el presentation de la provincia del la provincia de la provincia
- 10 The presence of FORS may be accomplished in a number of ways such as by Western blotting and ELISA procedures. A wide range of immunoassay techniques are available as can be seen by reference to U.S. Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct 15% binding of a labeled antibody to a target with the second of the sec

t of the latest of the executation of the commentation of the contribution of the first of the contribution of

Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical 20 % forward assay, an unlabeled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labeled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time 25 sufficient for the formation of another complex of antibody antigen-labeled antibody. As stated above, the antigen is FORS or a fragment thereof. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantified by comparing with a control ample containing known 30 amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labeled antibody are added simultaneously to the bound antibody. These in the property of the second

Frankling of the

Service and the contract of

techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention, the sample is one which might contain FORS including cell extract or tissue biopsy. As FORS is an intracellular molecule, cell extracts and in particular cytoplasmic extracts are preferred. The sample is, 5 therefore, generally a biological sample comprising biological fluid.

In a typical forward sandwich assay, a first antibody having specificity for the FORS or tik i Sieve ausze antigenic parts thereof, is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose. 10 polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex to the solid surface, which is then washed in preparation for the 15 test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if more convenient) and under suitable conditions (e.g. from room temperature to about 37°C including 25°C) to allow binding of any sub-unit present in the antibody. Following the incubation period, the antibody sub-unit solid phase is washed and dried and incubated 20 with a second antibody specific for a portion of the antigen. The second antibody is linked to a reporter molecule, which is used to indicate the binding of the second antibody to the antigen. The entrological of the community of the property of the property of the control 
An alternative method involves immobilizing the target molecules in the biological sample 25 and then exposing the immobilized target to specific antibody, which may or may not be labeled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labeling with the Decrease the second antibody:

Barcason ou segre, de 190 milious com la rocada Barcaso (C.C.). Estado escribir en combesión acesticado de com

DESCRIPTION AND THE SECOND SEC

16870 0074**6866**074960 **2**008

and the constitution of th

833 i i

o de alla de la composição 
Alternatively, a second labeled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule. 

By "reporter molecule", as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are enzymes, fluorophores or radionuclide-containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

To restrict the second state of the control of the

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase,  $\beta$ -galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted 20 above. In all cases, the enzyme-labeled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigenantibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantified, usually spectrophotometrically, 25 to give an indication of the amount of hapten which was present in the sample. "Reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like. 

Alternately, fluorescent compounds, such as fluorescein and rhodamine may be 30 chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labeled antibody

absorbs the light energy, inducing a state to excitability in the molecule, followed by
emission of the light at a characteristic color visually detectable with a light microscope.

As in the EIA, the fluorescent-labeled antibody is allowed to bind to the first antibodyhapten complex. After washing off the unbound reagent, the remaining tertiary complex is
then exposed to the light of the appropriate wavelength, the fluorescence observed
indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques
are both very well established in the art and are particularly preferred for the present
method. However, other reporter molecules, such as radioisotope, chemiluminescent or
bioluminescent molecules, may also be employed.

at the time of the problem of the contract of

The present invention is predicated in part on the determination that aberrant cells and in particular cancer cells and even more particularly mammary cancer cells or cells with a propensity for developing into mammary cells express elevated levels of FORS relative to normal cells. FORS is a phosphoprotein, which is demonstrated herein to be associated with inter alia cellular transformation. Moreover, its over-expression correlated with the up-regulation of the ErbB/HER2 receptor, over-expression of which in 30% of human breast cancer cases is known to be associated with poor prognosis. Hence, a cell that produces high levels of the FORS protein is deemed, in accordance with the present invention, to be an aberrant cell and a cell associated with or likely to be associated with a 20 disease such as cancer and, in particular, mammary cancer. The ability to detect FORS, or expression products of genetic material Fors which encodes FORS, provides a means for detecting or diagnosing cancer or a propensity for the development of cancer.

Accordingly, in another aspect, the present invention contemplates a method for detecting

25 an aberrant cell in a subject or in a biological sample from said subject, said method

comprising contacting cells or cell extracts from said subject or said biological sample with

an immunointeractive molecule specific for FORS or an antigenic portion thereof and

screening for the level of immunointeractive molecule-FORS complex formations wherein

an elevated presence of said complex relative to a normal cell is indicative of an aberrant.

30 cell

THE PROPERTY OF SECURISHING SECTION OF THE PROPERTY OF THE SECTION OF THE PROPERTY OF THE SECTION OF THE SECTIO

In a related embodiment, the present invention provides a method for detecting an aberrant cell in a subject or in a biological sample from said subject, said method comprising screening the level of an expression product of a gene encoding a FORS, wherein an elevated level of said expression product compared to a normal cell is indicative of an aberrant cell.

A "biological sample" from a subject includes a biopsy and may be any sample of cells, cell extract, tissue, tissue fluid, excretia, circulatory fluid or respiratory fluid or other material. The biological sample may be extracted, treated, untreated, diluted or concentrated from the subject.

Reference to a "normal" cell includes a cell not regarded as aberrant or cancerous and may be considered an "average" of normal cell types.

- The "immunointeractive molecule" is any molecule having specificity and binding affinity for FORS or its antigenic parts or its homologues or derivatives. Although the preferred immunointeractive molecule is an immunoglobulin molecule, the present invention extends to other immunointeractive molecules such as antibody fragments, single chain antibodies, de-immunized including humanized antibodies and T-cell associated antigenbinding molecules (TABMs). Most preferably, the immunointeractive molecule is an antibody such as a polyclonal or monoclonal antibody. Most preferably, the antibody is a monoclonal antibody.
  - The immunointeractive molecule exhibits specificity for FORS or more particularly an 25 antigenic determinant or epitope on FORS. An antigenic determinant or epitope on FORS includes that part of the molecule to which an immune response is directed. The antigenic determinant or epitope may be a B-cell epitope or where appropriate a T-cell epitope. The term "antigenic part" includes an antigenic determinant or epitope.
  - 30 As described above, an "expression product" may be an mRNA or cDNA and the amount of expression product provides an indicator of the level of Fors gene expression and

the beautiful to the agreem.

内性的特别的 (1000) (1000)

Z Pakanininini (Angratika da Angratika Kananini (Kananina Kananina Angratika Kananina Kananina Kananina Kanani

provides, therefore, indirect evidence for the presence of FORS protein. Conveniently,

pools of mRNA or cDNA are obtained or cell extracts comprising total mRNA obtained

and genetic probes complementary to all or part of the Fors gene-specific mRNA or

cDNA. Binding of probes may then be quantified or semi-quantified.

Reference to a "level" of FORS includes an amount quantitatively, semi-quantitatively or qualitatively determined.

Maria di Para Santa di Maria Maria Maria di Maria di Maria di Maria di Maria di Maria Maria di Maria d

In accordance with the present invention, it is proposed that cells associated with a cancer 10 and in particular mammary cancer cells produce elevated levels of FORS. The quantitative or qualitative detection of levels of FORS or expression products of genetic material encoding FORS provides, therefore, an indicator that the cell is aberrant and is associated with cancer or has a propensity to develop into a cancer.

ti e diktore dia ketikota dikan Mililia pelakarataan era ediake, keta daharat india dikibere dekimban keta dik

the presence of cancer or cancer-like growth in a subject, said method comprising contacting cells or cell extracts from said subject or a biological sample from said subject with a FORS-binding effective amount of an antibody having specificity for said FORS or an antigenic determinant or epitope thereon and then quantitatively or qualitatively determining the level of a FORS-antibody complex wherein the presence of elevated levels of said complex compared to a normal cell is indicative of the presence of a cancer.

In a related embodiment, the present invention provides a method for diagnosing the presence of a cancer in a subject, said method comprising obtaining mRNA from cells of said subject or from a biological sample from said subject and optionally generating cDNA and contacting said mRNA or cDNA with a genetic probe capable of hybridizing to and/or amplifying all or part of a *Fors* nucleotide sequence encoding FORS or its complementary nucleotide sequence and then detecting the level of said mRNA or cDNA wherein the presence of elevated levels of said mRNA or cDNA compared to normal controls is indicative of the presence of cancer.

TO BE A SERVED TO A SERVED SERVED SERVED SERVED DE SERVED DE SERVED SERVED SERVED SERVED SERVED SERVED SERVED

The use of antibodies and, in particular, monoclonal antibodies to detect FORS is the preferred method for use in this aspect of the present invention. Antibodies may be prepared by any of a number of means, as have been described above. Allina and market and a second and a second of the second and the second and the second and the second and the

5 The present invention further contemplates the use of competitive drug screening assays, in which neutralizing antibodies capable of specifically binding the FORS polypeptide compete with a test compound for binding to the FORS polypeptide or fragments thereof. NA 86353790 In this manner, the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants of the FORS polypeptide. Such screening methods are 10 \* not limited to assays employing only FORS, but are also applicable to studying FORSprotein complexes. The effect of drugs on the activity of this complex is analyzed.

Following identification of a substance that modulates or affects polypeptide activity, the substance may be investigated further. Furthermore, it may be manufactured and/or used in 15 preparation, i.e. manufacture or formulation or a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals in a method of treatment or prophylaxis. 

The identification of FORS as a tumorigenesis-related molecule permits the generation of 20 targeting agents to destroy or at least retard the growth of the cancer cells. In particular, the cancer targeting agents comprising FORS-specific antibodies are fused, bound or otherwise associated with a cell growth inhibiting or killing agent. Such agents include but are not limited to cytocidal or cytostatic agents which act at the protein or corresponding mRNA or DNA levels. For example, the cell growth or killing agent maybe a nuclear tag 25 or may be an agent which promotes induction of antagonists of FORS RNAi or RNA oligonucleotides. and a final state of the compact state, and otherwise for a contract of the contract of the contract of the

Accordingly, another aspect of the present invention contemplates a method for the treatment of a patient having cancer, said method comprising administering to said human, 30 a cancer cell growth inhibiting-effective amount of an antibody having specificity for human FORS protein, wherein said antibody is substantially non-immunogenic and further – Austria di Santo del algun de seguida de 

**进场作品的联系统规则是 1987年**。

Committee and the second of the

ośc)

PiOper\En.pro/s1007x159947.5thl\Sex.pro/s66-13/13/01

NA PARTE 
comprises a cell growth inhibiting or cell killing agent fused, bound or otherwise associated thereto. 

- The present invention further contemplates compositions comprising the cancer targeting 5 agents of the present invention and one or more pharmaceutically acceptable carriers and/or diluents. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions. It must be stable under the conditions of manufacture and storage and A CONTRACTOR must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dilution medium comprising, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of superfactants. The prevention of the action of microorganisms can be brought about by various anti-bacterial and anti-fungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like. In many 15 cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin. ta en el locazione, centro e estato trasse a sociativa de estato estato de en la compania de la compania de la
  - 20 Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with the active ingredient and optionally other active ingredients as required, followed by filtered sterilization or other appropriate means of sterilization. No for Kindy to the work of the control of the second of the property of the control of the second of the second

. Tara dekararar anterior area de la celo area al celo area en como con especial de la como en como en como en l

TO SOLD PROPERTY OF THE

25. Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art and except insofar as any conventional media or agent is incompatible with the active ingredient, their use in the therapeutic compositions is 30 contemplated. Supplementary active ingredients can also be incorporated into the compositions.

MATERIAL PRODUCTION OF THE

CENTRAL PROPERTY OF CONTRACTOR AND CONTRACTOR

and the second and the second 
The active agent is preferably administered in a therapeutically effective amount. The actual amount administered and the rate and time-course of administration will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc. is within the responsibility of general practitioners or specialists and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Pharmaceutical Sciences, 18th Ed. (Mack Publishing Company, Easton, PA, U.S.A., 1990).

Thus, the present invention extends to a pharmaceutical composition, medicament, drug or other composition comprising FORS, a fragment thereof or a FORS antagonist or mimetic thereof, or a FORS-specific antibody, associated with a cell growth inhibiting or killing agent, a method comprising administration of such a composition, a method comprising administration of such a composition to a patient, e.g. for treatment (which may include preventative treatment) of cancer, use of such a composition in the manufacture of a composition for administration, e.g. for treatment of cancer, and a method of making a pharmaceutical composition comprising admixing such a substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients:

A substance identified may be peptide or non-peptide in nature. Non-peptide "small molecules" are often preferred for many in vivo pharmaceutical uses. Accordingly, a mimetic or mimic of the substance (particularly if a peptide) may be designed for pharmaceutical use. The designing of mimetics to a known pharmaceutically active compound is a known approach to the development of a pharmaceutical based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesize or where it is unsuitable for a particular method of administration, e.g. peptides are unsuitable active agents for oral compositions as they tend to he quickly degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing are generally used to avoid randomly screening large numbers of molecules for a target property.

- 43 -

There are several steps commonly taken in the design of a mimetic from a compound having a given target property. First, the particular parts of the compound that are critical and/or important in determining the target property are determined. In the case of a peptide, this can be done by systematically varying the amino acid residues in the peptide, 5 e.g. by substituting each residue in turn. Alanine scans of peptide are commonly used to refine such peptide motifs. These parts or residues constituting the active region of the compound are known as its "pharmacophore".

Once the pharmacophore has been found, its structure is modeled according to its physical 10 properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, e.g. spectroscopic techniques, x-ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this modeling and who are approcess. While the control of the con

kaman na nakaman kalaman kaman kaman na kaman kaman kaman kan dan dan kan kaman kaman kaman kan kan dan dan da

In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modeled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this in the design of the mimetic.

A template molecule is then selected, onto which chemical groups that mimic the pharmacophore can be grafted. The template molecule and the chemical groups grafted onto it can conveniently be selected so that the mimetic is easy to synthesize, is likely to be pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of the lead compound. Alternatively, where the mimetic is peptide-based, further stability can be achieved by cyclizing the peptide, increasing its rigidity. The mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimization or modification can then be carried out to arrive at one or more final mimetics for in vivo or clinical testing.

a de la libre de la completa de la c

2012年1月17日 1911日 1915年 1911日 1915日 191 1815年 1915日 1

The second and the second seco

ALBANI AMERIKAN MENENTERSA MENGANDAN BERMANAN PER

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest, or of small molecules with which they interact (e.g. agonists, antagonists, inhibitors or enhancers), in order to fashion drugs which are, for example, more active or stable forms of the polypeptide, or which, e.g. enhance or interfere with the 5 function of a polypeptide in vivo See, e.g. Hodgson (Bio/Technology 9: 19-21, 1991). In one approach, one first determines the three-dimensional structure of a protein of interest (e.g. FORS) or, for example, of a FORS substrate or FORS-ligand complex, by x-ray crystallography, by computer modeling or most typically, by a combination of approaches. Useful information regarding the structure of a polypeptide may also be gained by 10 modeling based on the structure of homologous proteins. An example of rational drug design is the development of HIV protease inhibitors (Erickson et al., Science 249: 527-533, 1990). In addition, peptides (e.g. FORS) are analyzed by an alanine scan (Wells, 1991). In this technique, an amino acid residue is replaced by Ala and its effect on the peptide's activity is determined. Each of the amino acid residues of the peptide is analyzed 15 in this manner to determine the important regions of the peptide.

It is also possible to isolate a target-specific antibody, selected by a functional assay and then to solve its crystal structure. In principle, this approach yields a pharmacophore upon which subsequent drug design can be based. It is possible to bypass protein crystallography 20 altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced banks of peptides. Selected peptides would then act as the pharmacophore.

A 25 CONTROL OF CONTROL OF SERVICE CONTROL OF SERVICE CONTROL OF A CONTROL OF SERVICE CON Thus, one may design drugs which, for example, interfere with FORS activity or stability or which act as inhibitors or antagonists of FORS phosphoprotein, or which interact with FORS phosphoprotein or interfere with the phosphorylation of FORS phosphoprotein in such a way as to prevent or diminish its activity. By virtue of the availability of cloned 30 Fors sequences, sufficient amounts of the FORS polypeptide may be made available to perform such analytical studies as x-ray crystallography. In addition, the knowledge of the

1.搬上的搬送了好,对一点一点各位,就是到在1860年的第二人就会的这个人的。人们也是被分为人的情况,这都没有多数的人的

- 45

FORS protein sequence provided herein will guide those employing computer modeling techniques in place of, or in addition to x-ray crystallography.

- According to the present invention, a method is also provided for reducing or downregulating Fors function in a cell that carries an active Fors gene. Removing such a
  function should suppress neoplastic growth in the recipient cells. The wild-type Fors gene
  or a part of the gene may be introduced into the cell in a vector such that the gene remains
  extra-chromosomal. In such a situation, the cell will express the gene from the extrachromosomal location. Alternatively, it may be integrated into the nuclear genome of the
  10 cell. If a Fors gene or a nucleic acid sequence comprising a portion of the Fors gene, or a
  nucleic acid sequence complementary to a Fors gene sequence or portion thereof, is
  introduced and expressed in a cell, it may lead to the down-regulation of the endogenous
  Fors gene present in the cell.
  - 15 The term "down-regulating" is used in its most generic sense and includes any and all means by which the expression of a gene is reduced, diminished or eliminated, whether at the transcriptional or the post-transcriptional level.
- Vectors for introduction of genes both for recombination and for extra-chromosomal

  20 maintenance are known in the art and any suitable vector may be used. Methods for introducing DNA into cells such as electroporation, calcium phosphate co-precipitation and viral transduction are known in the art and the choice of method is within the competence of the practitioner.

A PARTIN MERSKAN FRANKE FOR FOR DER SER SER SER SER FRANKE EIN DER SER FRANKE FOR FRANKE FOR FRANKE FOR FRANKE

t land, the later with self-depoted and the control of the control

[2015] - 1017] (446) (1016) (2014) (466) (2014) (2017) (2017) (2014) (2016) (2016) (2016) (2016) (2016) (2016)

TO A POTENTIAL PROPERTY OF A STANK OF THE PARTY.

25 As generally discussed above, the Fors gene or fragment, where applicable, may be employed in gene therapy methods in order to down-regulate gene expression and thereby decrease the amount of the expression products of such genes in cancer cells. Such gene therapy is particularly appropriate for use in both cancerous and pre-cancerous cells, in which the level of FORS polypeptide is absent or diminished compared to normal cells.

fáti filat þafei teravækkeileri

One for of gene therapy is carried out according to generally accepted methods, for example, as described by Friedman (In: Therapy for Genetic Disease, T. Friedman, Ed., Oxford University Press, pp. 105-121, 1991) or Culver (Gene Therapy: A Primer for Physicians, 2<sup>nd</sup> Ed., Mary Ann Liebert, 1996). Cells from a patient's tumor would be first analyzed by the diagnostic methods described above, to ascertain the production of FORS polypeptide in the tumor cells. A virus or plasmid vector, containing a copy of the Fors gene linked to expression control elements is prepared. The vector may be capable of replicating inside the tumor cells. Suitable vectors are known, such as disclosed in U.S. Patent No. 5,252,479, International Patent Publication No. WO. 93/07282 and U.S. Patent No. 5,691,198. The vector is then injected into the patient, either locally at the site of the tumor or systemically (in order to reach any tumor cells that may have metastasized to and the Stephinist of the other sites). If the transfected gene is not permanently incorporated into the genome of each of the targeted tumor cells, the treatment may have to be repeated periodically. The present inveniton further contemplates using sense sequences of Fors to induce cosuppression or other forms of post transcriptional gene silencing as well as any mechanism involving RNA<sub>2</sub> and/or epigenetic mechanisms to silence gene expression.

THE SANGER WAS THE STATE OF SANGER STATE OF THE SANGE OF

Gene transfer systems known in the art may be useful in the practice of the gene therapy methods of the present invention. These include viral and non-viral transfer methods. A number of viruses have been used as gene transfer vectors or as the basis for preparing gene transfer vectors, including papovaviruses (e.g. SV40, Madzak et al., J. Gen. Virol. 73: 1533-1536, 1992), adenovirus (Berkner, Curr. Top. Microbiol. Immunol. 158: 39-66, 1992; Berkner et al., BioTechniques 6: 616-629, 1988; Gorziglia and Kapikian, J. Virol. 66: 4407-4412, 1992; Quantin et al., Proc. Natl. Acad. Sci. USA 89: 2581-2584, 1992; Sosenfeld et al., Cell 68: 143-155, 1992; Wilkinson et al., Nucleic Acids Res. 20: 2233-2239, 1992; Stratford-Perricaudet et al., Hum. Gene Ther. 1: 241-256, 1990; Schneider et al., Nature Genetics 18: 180-183, 1998), vaccinia virus (Moss, Curr. Top. Microbiol. Immunol. 158: 25-38, 1992; Moss. Proc. Natl. Acad. Sci. USA 93: 11341-11348, 1996), adeno-associated virus (Muzyczka, Curr. Top. Microbiol. Immunol. 158: 97-129, 1992;

30 Ohi et al., Gene 89: 279-282, 1990; Russell and Hirata, Nature Genetics 18: 323-328, 1998), herpesviruses including HSV and EBV (Margolskee, Curr. Top. Microbiol.

KO EWSTER

TENTO I WINDS AND BEAUTIFUL SERVICES OF THE TENTON OF THE PROPERTY OF THE PROP

Contract to the contract of a second and a second 
Park of the energy provide agency to be the co

The said the said of the said

-47-

Immunol. 158: 67-95, 1992; Johnson et al., J. Virol. 66: 2952-2965, 1992; Fink et al., Hum. Gene Ther. 3: 11-19, 1992; Breakefield and Geller, Mol. Neurobiol. 1: 339-371, 1987; Freese et al., Biochem. Pharmacol. 40: 2189-2199; 1990; Fink et al., Ann. Rev Neurosci. 19: 265-287, 1996), lentiviruses (Naldini et al., Science 272: 263-267, 1996),

. .

William Strain Strain Control

- 5 Sindbis and Semliki Forest virus (Berglund et al., Biotechnology 11: 916-920, 1993) and retroviruses of avian (Bandyopadhyay and Temin, Mol. Cell. Biol. 4: 749-754, 1984; Petropoulos et al., J. Viol. 66: 3391-3397, 1992], murine [Miller, Curr. Top. Microbiol. Immunol: 158:1-24, 1992; Miller et al., Mol. Cell Biol. 5: 431-437, 1985; Sorge et al., Mol. Cell. Biol. 4: 1730-1737, 1984; Mann and Baltimore, J. Virol. 54: 401-407, 1985;
- 10 Miller et al., J. Virol. 62: 4337-4345, 1988] and human [Shimada et al., J. Clin. Invest. 88: 1043-1047, 1991; Helseth et al., J. Virool. 64: 2416-2420, 1990; Page et al., J. Virol. 64: 5270-5276, 1990; Buchschacher and Panganiban, J. Virol. 66: 2731-2739, 1982] origin. Most human gene therapy protocols have been based on disabled murine retroviruses although adenovirus and adeno-associated virus are also being used.

- Non-viral gene transfer methods are known in the art such as chemical techniques including calcium phosphate co-precipitation, mechanical techniques, for example, microinjection, membrane fusion-mediated transfer via liposomes and direct DNA uptake and receptor-mediated DNA transfer. Viral-mediated gene transfer can be combined with direct in vivo gene transfer using liposome delivery, allowing one to direct the viral vectors to the tumor cells and not into the surrounding non-dividing cells. Alternatively, the retroviral vector producer cell line can be injected into tumors. Injection of producer cells would then in the latest the comprovide a continuous source of vector particles.
  - na slatia antainne fathasí séasach a sna cois ansa fastas plácasachtas a leistig agus an leistige coise a se In an approach which combines biological and physical gene transfer methods, plasmid DNA of any size is combined with a polylysine-conjugated antibody specific to the adenovirus hexon protein and the resulting complex is bound to an adenovirus vector. The trimolecular complex is then used to infect cells. The adenovirus vector permits efficient binding, internalization and degradation of the endosome before the coupled DNA is damaged. For other techniques for the delivery of adenovirus based vectors, see U.S. Patent No. 5,691,198.

w andra

The Edition of State of State of the State of the State of State o

Liposome/DNA complexes have been shown to be capable of mediating direct in vivo gene transfer. While in standard liposome preparations the gene transfer process is non-specific, localized in vivo uptake and expression have been reported in tumor deposits, for example, Prince Second Selection of the Computer Administration of the Computer Selection of the Computer

i a de militaria de cidade a condicio mánho e está il lata de inicianda de la laboració de la bacada de la definida en consideració de la definida del definida de la definida del definida de la definida del definida de la definida de la definida de la definida del definida de la definida de la definida de la definida del definida del definida del definida de la definida del del deligio del deligio del deligio del deligio deligio del deligio de Expression vectors in the context of gene therapy are meant to include those constructs containing sequences sufficient to express a polynucleotide that has been cloned therein. In viral expression vectors, the construct contains viral sequences sufficient to support 10 packaging of the construct. If the polynucleotide encodes FORS, expression will produce FORS. If the polynucleotide encodes a sense or antisense polynucleotide or a ribozyme or DNAzyme, expression will produce the sense or antisense polynucleotide or ribozyme or DNAzyme. Thus, in this context, expression does not require that a protein product be synthesized. In addition to the polynucleotide cloned into the expression vector, the vector 15 also contains a promoter functional in eukaryotic cells. The cloned polynucleotide sequence is under control of this promoter. Suitable eukaryotic promoters include those described above. The expression vector may also include sequences, such as selectable ESPANS DESIGN SECRETE SECTION AND CONSIDER OF THE SECTION OF THE markers and other sequences described herein.

20 The therapy is as follows: patients who carry a Fors gene are treated with a gene delivery vehicle such that some or all of their precursor cells receive at least one additional copy of said gene, in sense or antisense and/or combinations thereof, so as to effect interference with the expression of the endogenous Fors sequence. In this step, the treated individuals thereby have reduced risk of development of the cancer to the extent that the expression of 25 the endogenous Fors gene has been prevented and/or diminished by the introduction of the additional copies of a part or all of a nucleotide sequence encoding FORS.

andrene en la martie de la marie de la comerció de sontra de la marie a comerció de martino, començano

Accordingly, in this embodiment, the present invention contemplates genetic constructs such as comprising antisense, sense and ribozyme constructs or RNA or RNA 30 oligonucleotides. Such genetic compositions are also referred to as DNA vaccination

Carlot Control (Service Control (Control (Contro

ka ing balan alambaya a balan s

49.4

The data to the same

compositions and are specifically directed to modulating expression, at the transcriptional or translational levels, of nucleotide sequences encoding a FORS protein. 

Accordingly, another aspect of the present invention contemplates a method for the 5 treatment of a patient having cancer, said method comprising administering to said patient, a genetic composition comprising a genetic construct which down-regulates expression of a Fors gene encoding FORS. nunitara e la libracació a Tantibo contaña de estática durante e llabal de la luce los carresticacións de la comica

More particularly, the present invention contemplates a method for the treatment of a 2 2 2 10 patient having cancer said method comprising administering to said patient, a genetic composition comprising a genetic construct comprising a nucleotide sequence substantially as set forth in SEQ ID NO:4 or a fragment thereof or a nucleotide sequence having at least about 40% similarity to SEQ ID NO:4 after optimal alignment or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 its complementary form under low stringency medical property of the conditions of the condit

versker i træner frakværde grædfik og erekking gjarge parkjer klim og ekking frakværd gjar er og klim kommer ken e Reference herein to "expression" includes down-regulating the steps of transcription, translation or both. Particularly preferred genetic constructs are antisense or sense constructs to FORS, which induce co-suppression of the Fors gene or induce RNAi 20. mediated down-regulation of Fors mRNA transcript.

In another aspect of the present invention, cells and animals which carry a Fors nucleic acid sequence can be used as model systems to study and test for substances which have potential as therapeutic agents. Cells may be isolated, for example, from individuals 25 expressing a Fors gene. Alternatively, a cell line may be engineered to carry the Fors gene or, in an alternative approach, an aberration in the Fors sequence. Mutating or deleting the Fors gene or an allele thereof has the ability to reduce or prevent its expression. The term "mutating", and related terms such as "mutate", "mutation" and "mutated", are used in their most generic sense and includes methylation of all or part of the nucleotide 30 sequences, and in particular cytosine or guanine residues, or other events which induces gene silencing.

P\*Oper\*E/ji: prior\$20020189867.withl. Bras pray doc-13/12/02

The term "aberration" encompasses all forms of mutations including deletions, insertions, point mutations and substitutions in the coding and non-coding regions of Fors. It also includes changes in methylation patterns of Fors or of an allele of Fors. Deletions may be 5 of the entire gene or only a portion of the gene. Point mutations may result in stop codons, frame-shift mutations or amino acid substitutions. Somatic mutations are those occurring only in certain tissues, e.g. in the tumor tissue and are not inherited in the germ-line. Germ-line mutations can be found in any of a body's tissues and are inherited. A Fors allele, which is not deleted (e.g. that found on the sister chromosome to a chromosome carrying a 10 Fors deletion), can be screened for other mutations such as insertions, small deletions, point mutations and changes in methylation pattern. Mutations leading to non-functional gene products may also lead to decreased prevalence of a cancerous state. Point mutational events may occur in regulator regions, such as in the promoter of the gene or in an intron of the gene, leading to loss or diminution of expression of the mRNA. Point mutations may 15 also abolish proper RNA processing leading to loss of expression of the Fors gene product or a decrease in mRNA stability or translation efficiency. Point and other mutations may also affect proper RNA processing such as intron splicing. en neutro de la la la compaño dos la los polos españos de la como de como de como de la como de la como la com

After a test substance is applied to the cells, the neoplastically-transformed phenotype of

20 the cell is determined. Any trait of neoplastically-transformed cells can be assessed,
including anchorage-independent growth, tumorigenicity in nude mice, invasiveness of
cells and growth factor dependence. Assays for each of these traits are known in the art.

ĝen.

2/%r #

Animals for testing therapeutic agents can be selected after mutagenesis of whole animals

25 or after treatment of germ-line cells or zygotes. Such treatments include insertion of Fors
genes, usually from a second animal species, and may also include insertion of disrupted
homologous genes. Alternatively, an endogenous Fors gene of an animal may be disrupted
by insertion or deletion mutation or other genetic alterations using conventional
techniques. After test substances have been administered to the animals, the growth of
tumors must be assessed. If the test substance prevents or suppresses the growth of tumors,
then the test substance is a candidate therapeutic agent for the treatment of the cancers

Torreson active BBC (\$850) in the control of the work to be seen from the control of the control

THE STATE OF THE S

A selfence and Garage and The mind open expansion

512

identified herein. These animal models provide an extremely important testing vehicle for potential therapeutic products. 

The identification of the association between the presence of FORS phosphoprotein and 5 cancer permits the early pre-symptomatic screening of individuals to identify those at risk for developing cancer. To identify such individuals, they are screened for the presence of FORS, or for Fors sequences or the presence of nucleic acid sequence differences from the normal gene using any suitable technique. Suitable techniques include but are not limited to, one of the methods hereinbefore described, i.e. fluorescent in situ hybridization (FISH), 10 direct DNA sequencing, PFGE analysis, Southern blot analysis, single-stranded conformation analysis (SSCP), linkage analysis, RNase protection assay, allele specific oligonucleotide (ASO), dot blot analysis and PCR-SSCP analysis, or DNA/RNA microchip technology. 

An alternative strategy is a large scale immunoaffinity purification of Fors-biomolecular complexes. The partners in the purified complex can then be eluted off and analysed.

Two-hybrid screening is particularly useful in identifying other members of a biochemical or genetic pathway associated with Fors. Two-hybrid screening conveniently uses 20 Saccharomyces cerevisiae and Saccharomyces pombe. FORS interactions and screens for inhibitors can be carried out using the yeast two-hybrid system, which takes advantage of transcriptional factors that are composed of two physically separable, functional domains (Phizicky and Fields, Microbiol. Rev. 59(1): 94-123, 1994). The most commonly used is the yeast GAL4 transcriptional activator consisting of a DNA binding domain and a 25 transcriptional activation domain. Two different cloning vectors are used to generate separate fusions of the GAL4 domains to genes encoding potential binding proteins. The fusion proteins are co-expressed, targeted to the nucleus and if interactions occur, activation of a reporter gene (e.g. lacZ) produces a detectable phenotype. In the present case, for example, S. cerevisiae is co-transformed with a library or vector expressing a 30 cDNA GAL4 activation domain fusion and a vector expressing a FORS-GAL4 binding domain fusion. If lacZ is used as the reporter gene, co-expression of the fusion proteins Alexandra or of these strongers are a Tilon in India Karakanan yan baran 1995



机压力 医二烷基化异氯甲基基酚 蒙古

编 经收益的 医电子

A STATE OF THE STA

n and wastifieth was him of Mar Nath, and Alamo, educated the speciment of the Alamon in the William Alamon, a

in the reason with a reason to be in a second part of the reason of the least of the second treat and reason.

"你你说,只要你看到这一点,我们就要不是一个心心,你都说,这么就要你一定,我们你是这个我们,我就是什么必须不能能,要是这是一

n die der des anniers des des sons de seus de des

and a final section of the first and the section of the

and a straight field againg the company of the property of the company of the field of the fiel

will produce a blue color. Small molecules or other candidate compounds which interact with FORS will result in loss of color of the cells. This system can be used to screen for small molecules that inhibit the FORS interaction and, hence, protect the yeast against cell death and to determine the residues in FORS which are involved in their interaction. For example, reference may be made to the yeast two-hybrid systems as disclosed by Munder et al. (Appl. Microbiol. Biotechnol. 52(3); 311-320, 1999) and Young et al., Nat. Biotechnol. 16(10): 946-950, 1998). Molecules thus identified by this system are then retested in animal cells.

t later from the fig. for the construction of the flow bear into the forest and a construction bearing the forest configuration in the first of the first configuration in the first of the first configuration in 
ALLETTERM CENTRAL AND ARTEST FOR A STANDARD OF THE COMPANIES OF A COMPANIES OF THE COMPANIES OF A SERVICE OF T

rentant de la franciène, que la combination de desarte de l'appetent de l'appetent de la française de la franç

kalimi erak dalam dan 1960 larga salika kalima dan larah 1960 dan dan darah dan kalimada da bada da kalimaka s

STORE OF A PREPARED TO PROBLEM TO SEE A SECTION OF THE PROPERTY OF THE REPORT OF THE PROPERTY OF THE SECTION OF

avidited took took has havind in hoodite took of an objective of in hard, have been all now have all and hard bedrain and high

to the contract for the contract of the contra

经收收证据 医骶骨骨骨 医皮肤 人名英格兰 医克斯特氏 医多种腺素 医皮肤 电电流 医二十二氏 医多氏性 经分价 医多氏性多数 化多效性 医腹腔性

Del Charle (1986). Walang da 1901 an da bar kampakang kalang kalang bar atah dan barang dan dilang barang dang

randiki iliyok isan balansa bala ingasir wilika berang amalim na mariken dibuna merikalangan bala dibun

一切哪个多数,只是一样的人,就因为,这几次的一种爱家,手架一只这一点的话说,一条的小孩的女子,也不知识了的爱好,不适应我的。

P. Vopet Eit: provis 2007 2389867 sechi Bry. prov. doi:-13/12/13

10 The present invention is further described by the following non-limiting Examples.

(1998年) 40年 (1994年) 1986年 (1886年) 1988年 (1998年) 1988年 (1994年) 1988年 (19

AND A CONTRACTOR OF SAME AND AND AND AND A

ante esta di la companya di mandala di manganta di mangan di mangan di mangan di mangan di mangan di mangan di

#### EXAMPLE 1

#### Reagents and mice

Karaden Kengalan dan dibanggan Kengalan dinanggan di Sunak di Rengalan Salanggan Salah Salah Kengalan Singgan

#### Reagents ...

Antibodies used were as follows: affinity purified rabbit polyclonal anti-phospho-FKHR (S256) antibody (New England Biolabs); mouse monoclonal anti-α-tubulin antibody (clone B-5-1-2; Sigma); mouse monoclonal anti-ErbB2 antibody (Ab-10; Neomarkers); mouse monoclonal anti-Neu antibody (Ab-3; Calbiochem); mouse monoclonal anti-Flag antibody (Sigma); anti-Pctpl polyclonal rabbit serum. Recombinant human EGF and insulin were purchased from Sigma.

### Mice

and Japan V

15 Mouse mammary tumor virus (MMTV)-Neu mice have been previously described (Guy et al. (2000), supra. Nulliparous female mice were aged for 8-12 months in standard animal la marka el el del del la lación de la lación facilities and were sacrificed when tumors developed.

SECTION SECTION OF A CONTROL OF

#### EXAMPLE 2

#### 20 Preparation of protein lysates

安徽·曾代统司 (46年)第三年(46年) (1864年) 1864年(1871年) 1月 (1871年) 1888 (1888) 1888 (1884) 1894 (1894) 1894 (1894)

To explore the potential inactivation of the FKHR transcription factor by ErbB receptor signaling, protein lysates prepared from mammary tumors derived from mouse mammary tumor virus (MMTV)-New transgenic mice. Whole cell extracts were obtained by 25. solubilizing cells in 1% NEB (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 20 mM β-glycerophosphate plus complete protease inhibitors (Roche)). Lysates were clarified by centrifugation at 16,000 x g for 10 min. Protein lysates of tissues were obtained by grinding the tissue to a fine powder under liquid nitrogen and subsequent solubilization in 1% TEB (NEB with substitution of NP40 30 with Triton X-100). Lysates were homogenized by passing through a 21-gauge needle prior to clarification by centrifugation. andre a care occide Timber of Million

For cytosolic protein extraction, cells were lysed in hypotonic buffer (10 mM Hepes, pH 7.9, 133 mM sorbitol, 0.5 mM sodium fluoride, 0.5 mM β-glycerophosphate plus complete protease inhibitors (Roche)), left to swell on ice for 10 min, homogenized by Douncing and then centrifuged at 800 x g for 10 min. The pellet was washed with hypotonic buffer and the supernatants were combined to yield the cytosolic fraction.

#### **EXAMPLE 3**

A tumor-specific 35 kDa protein cross-reacts with a phosphospecific

FKHR antibody

Mammary tumor lysates were analyzed by Western blotting, using an antibody that specifically recognizes FKHR phosphorylated on serine 256 (Figure 1A).

15 The proteins were blotted onto polyvinylidine difluoride membranes (Millipore). After blocking with 20% v/v horse serum (Hunter) in PBS containing 0.1% v/v Tween-20, filters were probed with specific antibodies. Proteins were visualized with peroxidase-coupled secondary antibody using the ECL detection system (Amersham). Stripping of membranes was performed in SDS buffer (62.5 mM Tris, pH 6.8, 2% v/v SDS, 100 mM β-20 mercaptoethanol) for 30 min at 60°C. Membranes were then re-probed with the indicated antibodies.

No signal corresponding to FKHR was detected in tumor or adjacent mammary tissue, reflecting the low level of FKHR expression. Interestingly, the phosphospecific FKHR

25 antibody strongly cross-reacted with a 35 kD protein that was present in tumor but not in adjacent or normal mammary tissue, as shown in Figure 1. Western blotting with an anti-Neu antibody confirmed over-expression Neu in these tumors.

Further analysis of several breast epithelial cell lines revealed that the 35kD protein was 30 absent in the immortalized breast epithelial cell lines HBL100 and 184 but could be

。在1996年中的海南,900年的,1968年19月5日,1996年,1997年,1988年1997年,1997年,1997年,1997年,1997年,1997年,1997年,1997年,1997年

detected in the majority of transformed cell lines (refer to Example 9, below, and to Figure 5C).

Since no FoxO family members corresponding to this molecular weight had been

5 described, it was hypothesized that the 35 kD protein might represent a novel FKHRrelated protein. This protein was likely to be phosphorylated on a serine residue lying in a
conserved sequence context, given the specificity of the FKHR-specific antibody.

## Warren & Cherry & Cherry & Control of the Control of the Example 4 to a March Control of the Con

Purification of the 35 kD protein

In order to identify the protein cross-reacting with the phospho-FKHR antibody, an immunoprecipitation with this antibody using SKBR3 cell lysate was performed.

- 15 For immunoprecipitations, equal amounts of protein were incubated with specific antibodies for 2 h on ice. Immune complexes were collected with protein G-Sepharose (Pharmacia) and washed three times with 1% NEB. For phosphorylation analysis, immune complexes were further washed with 10 mM Tris, pH 8, 100 mM NaCl, before being incubated in the same buffer with 5 units of alkaline phosphatase (Roche) for 45 min at 20 37°C. Precipitated proteins were released by boiling in sample buffer and were subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) using 4-20% gradient gels (Novex).
  - While the antibody readily detected the 35 kDa protein by Western blotting, it failed to

    25 immunoprecipitate the protein. A multi-step biochemical purification strategy was
    therefore devised, based on parameters such as isoelectric focusing point, hydrophobicity
    and molecular weight of the protein. Since the 35 kD protein was demonstrated to be
    cytosolic, protein lysates from SKBR3 cells were prepared by hypotonic lysis using
    conditions that are compatible with isoelectric focusing (IEF). An analytical sample of

    SKBR3 cytosol was initially analyzed by free flow electrophoresis (FFE), a liquid based
    isoelectric focusing method.

JOSEPH CONTROL OF THE WAR AND A SECOND

u tradition confidences and a less a

FFE was essentially performed as described in Hoffmann et al., Proteomics 1: 807-818,

2001, using the Octopus apparatus. The IEF running buffer was aqueous 0.2% w/v HPMC

(hydroxypropyl methyl cellulose) and 0.2% w/v carrier ampholytes (Servalyte pH 3-10).

5 Electrode solutions were 100 mM H<sub>3</sub>PO<sub>4</sub> (anode) and 50 mM NaOH (cathode); the counter flow solution (0.7 l/min) was 0.2% HPMC containing 0.02 M L-arginine and 0.02 M L-lysine. For preparative separations, the sample was diluted to a final concentration of approximately 0.25 mg protein per ml. Electrophoresis was performed at 4°C with a flow-rate of 1.4 ml/min and a constant voltage of 1250 V.

This continuous mode of isoelectric focusing is especially advantageous for protein purification when large volumes of cell lysate are required. As shown in Figure 2A,

Western blotting of individual fractions using the phospho-FKHR antibody revealed the presence of two protein bands with distinct isoelectric focusing points, corresponding to pH 5.6 and pH 6. This shift may reflect differential phosphorylation.

To test whether the 35 kD protein could be effectively separated by reverse phase HPLC, SKBR3 cytosol was subjected to RP-HPLC. The 35 kD protein was found to elute in specific fractions, as shown in Figure 2B.

For preparative purification of the 35 kD protein, 275 mg of cytosolic protein was applied to FFE followed by RP-HPLC. Fractions containing the 35 kD protein were identified by Western blotting using the phospho-FKHR antibody, then pooled (7 mg) and subjected to RP-HPLC. HPLC fractions containing the 35 kD protein were pooled and precipitated by addition of 0.5% w/v deoxycholate and 15% v/v. TCA plus two volumes of acetone at -20°C. After centrifugation at 16,000 x g for 15 min, the protein pellet was washed with acetone, briefly left to dry and resupended in sample buffer. A large 10% w/v gel was poured according to Laemmli and electrophoresis was performed at 150 V for 6 hours. The gel was fixed and stained with Coomassie Phast-gel Blue R (Pharmacia, UK) (Figure 2C).

The bands migrating at approximately 35 kD were excised, digested in situ with trypsin and analyzed by tandem mass spectrometry. All peptides from band #1 matched an entry in the Trembl database, Q9Y365, a predicted human protein based on a comparative screen of the C. elegans proteome with human est nucleotide databases (Lai et al., Genome Research 5 10: 703-713, 2000). Alignment of this sequence with the FKHR protein failed to identify a forkhead domain but instead identified a region in Q9Y365 that was highly similar to the sequence surrounding serine 256 to which the phospho-FKHR antibody had been raised (Figure 2D). Most importantly, this sequence in Q9Y365 contained a serine that (i) aligned with S256 in FKHR and (ii) obtained a high score in the Netphos phosphorylation 10 prediction program. It, therefore, appeared likely that this protein, when phosphorylated on this serine residue, would cross-react with the FKHR-specific antibody.

## To a large transfer and the second state of the second sec

#### Cloning and expression analysis of the 35 kD protein, FORS

aret etak iki**.15**55a - Eta e kantonar Kiran Pauli san Iraan Arandar etak injan Sandar etaken Jakon Jaton Kalon ak esta ka a kanton k

Sequence analysis of Q9Y365 predicted a molecular weight of 40 kD and a pI of 8.55, higher than the experimentally observed values of the 35 kD protein. No sequence coverage of the first 71 amino acids was obtained, suggesting that translation was initiated from the methionine at position 68, giving rise to a protein of 291 amino acids with a 20 theoretical mass of 33kD and a pl of 6.7. These calculations do not take into account the presence of phosphorylation sites, which would render the protein more acidic (Figure 3A) ki diversi kara kemilika dalam kemilika dalam kemilika dalam kemilika dalam kemilika dalam kemilika dalam kemi and would decrease the electrophoretic mobility in SDS-PAGE.

na na katangan katangan makan dalah salah katangan katangan katan dan dan dan dan katangan katangan salah <mark>k</mark>asa

DESCRIPTION OF THE PROPERTY OF

Full-length cDNA encoding a 33 kD protein product was generated by RT-PCR using 25 RNA derived from SKBR3 cells, Total RNA was extracted from SKBR3 cells using RNAzol (Tel-Test). First strand cDNA synthesis was performed and Fors cDNA was amplified by PCR using primers based on the CGI-52 sequence (Accession No. AF151810). Fors cDNA was cloned into HA-pcDNA3.0, Flag-pEFrPGKpuro and pBabePuro for expression in mammalian cells. An HA or Flag tag was incorporated at the 30 N-terminus within the pcDNA3.0 or pEF-1 arev expression vectors, respectively, to facilitate recognition.

a o California de la California de la California de California de California de California de California de Ca

Remarkably, transient expression of the HA-tagged expression plasmid in 293T cells gave rise to a protein that was detected by the phospho-FKHR antibody (Figure 3B). The slight difference in size compared to the endogenous protein is most likely due to the presence of the tag. Recognition of this protein was phosphorylation-dependent, since treatment of immunoprecipitated Flag-tagged protein with alkaline phosphatase abrogated the cross-reactivity. This suggests that serine 259 in the 35 kD protein is indeed phosphorylated.

This protein was, therefore, termed FORS (forkhead related serine).

acid protein from a mouse testis library. The mouse sequence does not indicate the presence of larger protein since there is no open reading frame encoding an amino-terminal extension, distinct from that observed in the human sequence.

Di Collegio Benni Peres (Del dicum Sarte de Leigio, Artica Peres di manda i profesiona del philipio estima de manda de manda de la collegio del collegio del collegio de la collegio della 
# EXAMPLE 6

Province 15 to the country and the second se

# Northern analysis of FORS mRNA

Poly(A)<sup>†</sup> RNA was isolated from breast epithelial cell lines and Northern analysis was

20 performed as described (Visvader, EMBO J. 11: 4557-4564, 1991). Briefly, 4 µg of
poly(A)<sup>†</sup> RNA was fractionated on 1% w/v agarose-formaldehyde gel, transferred to
Hybond N<sup>†</sup> (Amersham Pharmacia Biotech), and hybridized with the following cDNA
probes: Fors cDNA, encompassing the entire 876 bp coding region or residues 769-876,
ErbB2 cDNA (residues 1-228), EGFR cDNA (residues 1-293) or GAPDH cDNA; Human

25 multiple poly(A)<sup>†</sup> RNA tissue Northern blots (Clontech Laboratories, Inc.) were
hybridized with a Fors cDNA probe.

Northern analysis of Fors mRNA from a variety of human organs revealed high levels of a

1.4 kb transcript in liver, heart, skeletal muscle and kidney. While a faint signal was

30 detected in placenta, organs such as brain, colon, thymus, spleen, small intestine, lung and

PBL cells lacked Fors mRNA.

en Puntano nom en un Palement annom la respecta de la respectación de la compaña establica de la company de la

tronger of the territory of the second section of the second seco

#### **EXAMPLE 7**

#### Co-expression of FORS and ErbB2 occurs at high levels in

### breast cancer cell lines

FORS levels were originally found to be abundant in tumors from Neu transgenic mice and in breast carcinoma cell lines using an antibody that recognizes the protein in a phosphorylation-dependent manner. To determine whether Fors up-regulation was occurring at the RNA level and whether it correlated with over-expression of ErbB2,

Northern analysis was performed, as described in Example 6, above, on a panel of breast epithelial cell lines (Figure 4A).

High levels of Fors were found in the cell lines that were previously shown to express phosphorylated FORS protein, indicating over-expression at the transcriptional level. Fors expression was barely detectable in both human and mouse immortalized cell lines (184, HBL100, Scp2, Eph4 and HC11). Interestingly, all cell lines that over-expressed ErbB2 mRNA were established to have higher Fors levels. Fors over-expression, however, was also noted in cell lines without a concomitant increase in ErbB2 expression.

An expression survey of human colon carcinoma cell lines suggested that over-expression of Fors might also be a feature of this tumor type (Figure 4B). Several cell lines expressed Fors to a level that was comparable to that seen in SKBR3 cells. However, there was no correlation between Fors and EGFR mRNA.

以来,如此如何**经**收入的基础。1975年,**201**5年,在1985年,1985

## THE 25 CONTROL DE LES CONTROL EXAMPLE 8

# Culture of cell lines

Breast epithelial cell lines were maintained in RPMI containing 10% v/v fetal bovine serum (FBS) (CSL) and 1 μg/ml insulin with the exception of MCF10A cells that were 30 grown in DME HAM supplemented with 10% μ FBS, 10 ng/ml EGF, 5 μg/ml insulin and 1 μM dexamethasone.

Picholes, princeorisises with fire in the City 1703.

293T, NIH3T3 and HER14 (NIH3T3 transfected with the human EGFR) and Bosc cell
lines were grown in DME medium containing 10% v/v FBS. NIH3T3 Fors and HER14
Fors were generated by stable introduction of a pBabe retrovirus encoding HA tagged Fors

5 using Bosc packaging cells and selection with 1 µg/ml puromycin (Sigma).

For transient transfections, 293T cells were transfected with Fugene reagent (Roche) according to the manufacturer's instructions.

#### EXAMPLE 9

Bankan er a helk bine rikk med de e e ringelik in be danke bink membelikin alle mit e dekommer de des ak bises

### Generation of FORS-specific antibodies

Database searches identified the presence of a Start domain in FORS (amino acid 21-226),
a phospholipid binding domain first noted in the steroidogenic acute regulatory protein

15 STAR. The Start domain of FORS is 28% identical and 49% similar to that of human Pctp
(phosphatidycholine transfer protein), a 214 amino acid protein which consists almost entirely of the Start domain. Unlike Pctp, FORS has a 65 amino acid carboxyterminal extension (Figure 5A).

er i det sterret de komment de set et er en skriver i findet en kommen en skriver et en er eller de letter de k

To generate an antibody specific for FORS, rabbits were immunized with a keyhole limpet hemocyanin (KLH; Sigma)-coupled peptide encompassing amino acids 265-277 at the C-terminus downstream of the Start domain. The peptide ESAVAESREERMG (SEQ ID NO:1) corresponding to amino acids 265-277 of FORS was selected, based on antigementy and surface availability predictions and synthesized with an additional aminoterminal cysteine (Auspep) for coupling to KLH. In brief, KLH was cross-linked with N-Succinimidyl 3-(2-pyridyldithio)propionate (Pierce) and added to peptide that had been reduced and purified with SepPak columns (Waters). Two rabbits (# 419 and 420) were injected subcutaneously with 200 μg peptide in complete adjuvants and boosted in 2 weekly intervals. Bleeds were tested by ELISA and Western blotting. Antibody purification from rabbit sera was performed with peptide that had been covalently coupled to Sulfolink coupling gel (Pierce) following the manufacturer's instructions. Elution was

n tiplica a talli natiola a care li to an nilagon, in la pagaza,

Martin Control of Market Control of the Control of

TO DESCRIPTION OF THE PARTY OF

carried out with 100 mM glycine, pH 2.7 and antibody-containing fractions were pooled and dialyzed against PBS.

### Maria Santa Caracteria de la compania del compania del compania de la compania del 
### Localization of FORS in breast epithelial cells

Upon affinity purification, both antibodies were found to specifically recognize human FORS protein (Figure 5B). Immunoblotting of breast epithelial cell lines confirmed that over-expression of phosphorylated FORS protein correlates with ErbB2 status in many 10 cases (Figure 5C).

Immunofluorescence of MCF7 cells was undertaken, with a FORS-specific antibody, using landar i Samaros eti confocal microscopy. Cells were plated onto cover-slips in 6-well dishes 24 hours prior to Yan region bearing immunostaining. Cells were fixed with 4% v/v paraformaldehyde in PBS for 10 min. 25 permeabilized with PBS-T (PBS containing 0.2 Triton X-100) and then blocked (5% goat serum (Hunter) in PBS-T) for 30 min. Cover-slips were incubated for 1 hour with affinity purified FORS-specific polyclonal antibody (#420) diluted in blocking solution. After washing with PBS-T, cover-slips were incubated with anti-rabbit secondary antibody conjugated to fluorescein isothiocyanate (The Jackson Laboratory). Cells were 20 counterstained with 1 μg/ml Bis-benzimide (Sigma) and cover-slips were then mounted onto slides with fluorescent mounting medium (Dako Corp., Carpinteria, CA). Cells were examined using a Leica Corp. TCS-4D confocal microscope. 

eradia de la proposición

William Charles of the Section

· 经产品的产品的主要的企业的 医人名西克尔

Results revealed punctate staining in the cytoplasm and some staining in the nucleus 25. Interestingly, FORS also appeared to be concentrated at the boundaries of cell clusters (Figure 5B). Scansite sequence analysis of FORS suggests that the carboxyterminus may harbor a PDZ domain recognition motif. It will thus be interesting to determine the intracellular compartment to which FORS localizes and whether its localization is controlled by PDZ interactions:

a de la Companió de

and the state of the

THE TOWNSHIP WAS A PROPERTY OF THE PARTY OF

# 

#### EXAMPLE 11 Fors cooperates with ErbB1 in cellular transformation

To investigate the effect of FORS over-expression on cell proliferation, NIH3T3 and 5 HER14 cells stably over-expressing Fors were generated by retroviral infection. The HER14 line represents NIH3T3 cells stably expressing the EGFR. Parental NIH3T3 and HER14 cells lack FORS, determined by Western blotting using an anti-Pctp2 antibody which recognizes both the mouse and human protein (Figure 6A). 

Si Gradina da Mar

10 Fors over-expression did not appear to alter the morphology of either NIH3T3 or HER14 cells. Growth was assessed by MTS assays, carried out by plating 2000 cells per well (96 well plate) in 100 μl culture medium containing 10% or 0.5% v/v FBS. The absorbance at 490 nm was determined with an Elisa plate reader after addition of 20 μl MTS reagent (Promega) and incubation at 37°C for 2 hours. Growth in normal and limiting serum 15 conditions was not affected by expression of FORS (Figure 6B). Furthermore, no difference in the growth rate was observed when EGF was added to HER14 Fors cells grown in 0.5% serum, compared to HER14 Puro control cells. However, Fors expression was found to enhance anchorage-independent growth of both NIH3T3 and HER14 cells. 

VV 44444 (1800)

- 20 Growth in soft agar was also assessed, as follows: 5 x 10<sup>4</sup> for NIH3T3 lines and 2-5 x 10<sup>3</sup> for HER14 lines were plated in duplicate or triplicate in 6 well plates in 2 ml culture medium supplemented with 0.35% Difco agar overlaying a 2 ml 0.7% bottom agar. For stimulation of the EGFR in HER14 lines, 10 ng/ml EGF was added to the top agar. The cells were incubated for four weeks and re-fed on a weekly basis with 300 ul culture 25 medium (with or without EGF for HER14 lines). Cells were stained by addition of 400 µl PBS containing 0.5 mg nitroblue tetrazólium (Sigma) for 24 hours before photographing using a Nikon SMZ-U microscope connected to an Axiocam digital camera (Zeiss). Photographs were analyzed using ImageJ software. and the second of the second and the second of the second
- 30 Introduction of Fors into NIH3T3 cells allowed outgrowth of few small colonies when 50,000 cells were plated per well (Figure 7A). HER14 cells are capable of growing in soft

The first constant of the same self-school by the constant of the same same self-school by

-63 -

agar and colony number and size can be increased by the addition of EGF. Expression of FORS in these cells doubled the number of colonies larger than 50 µm in diameter and colonies also reached a larger size (Figures 7B and 7C). Taken together, these results suggest that FORS specifically affects anchorage independent proliferation, a crucial feature of cellular transformation, and that it functions synergistically with the EGFR.

NIH3T3 cells expressing Fors are tested for an ability to form tumors in nude mice. Furthermore, HER14 Fors cells are examined to ascertain whether they have a growth advantage in vivo compared HER14 Puro control cells.

#### **EXAMPLE 12**

## Fors is over-expressed in primary human breast cancers

atara talenta (alemana da desenaren aren aren aren errakoaren barren errakoaren errakoaren errakoaren errakoar

A polyclonal antibody, highly specific for FORS by Western blotting and 15 immunofluorescence, has been generated. Using this antibody, staining of histological sections of human breast tumors addresses the question of whether FORS up-regulation is linked to tumor grade and useful as a prognostic marker. These histological examinations of the FORS protein are extended to other tumor types, such as colon carcinoma. Present results indicate that FORS up-regulation may be of significance in a subset of human colon 20 carcinoma cell lines. Moreover, screening of a cDNA expression library derived from a human colon tumor patient with autologous serum identified auto-antibodies raised against FORS (Scanlan et al., Int. J. Cancer 75: 652-658, 1998), indicating that FORS may be a take the control of target for antitumoral immune response and the same of the

25 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or

um erálős kernelőszárásanta. Tye

TO A STATE OF THE 
more of said steps or features.

Marin Marin St. A. Landin (1977) C. L. L. L.

Policie (Co. Proce

Windski ar sludbyda, 🚧

taki kuyang punihan

ránástus etropis s

Ži 1886 i saskina

選挙が まったい

ka Kabupatèn

- 64

THE CAND MADE & DESCRIPTION OF SE

## BIBLIOGRAPHY

restatibulies es delitimina Xiliai (1770 es 1966) (1786 es 1786)

Altschul et al., Nucl. Acids Res. 25: 3389-3402. 1997.

Ausubel et al., "Current Protocols in Molecular Biology" John Wiley & Sons Inc, 1994-1998, Chapter 15:

Bandyopadhyay and Temin, Mol. Cell. Biol. 4: 749-754, 1984.

Beaucage and Carruthers, Tetra. Letts. 22: 1859-1862, 1981. i kangambaran kan kacamatan mengan basa

Berglund et al., Biotechnology 11: 916-920, 1993.

Berkner et al., BioTechniques 6; 616-629, 1988.

Berkner, Curr. Top. Microbiol. Immunol. 158: 39-66, 1992

Bonner and Laskey, Eur. J. Biochem. 46: 83, 1974.

Breakefield and Geller, Mol. Neurobiol. 1: 339-371, 1987.

Buchschacher and Panganiban, J. Virol. 66: 2731-2739, 1982.

Culver, Gene Therapy: A Primer for Physicians, 2nd Ed., Mary Ann Liebert, 1996.

Douillard and Hoffman, Basic Facts about Hybridomas, in Compendium of Immunology Vol. II, ed. by Schwartz, 1981. Control Committee and the control of 
Enhancers and Eukaryotic Gene Expression, Cold Spring Harbor Press, Cold Spring Harbour, New York, 1983.

Erickson et al., Science 249, 527-533, 1990.

Fiers et al., Nature 273: 113-120, 1978.

Fink et al., Ann. Rev. Neurosci. 19: 265-287, 1996.

Fink et al., Hum. Gene Ther. 3: 11-19, 1992.

Freese et al., Biochem. Pharmacol. 40: 2189-2199, 1990.

Friedman, In: Therapy for Genetic Disease, T. Friedman, Ed., Oxford University Press, pp.

romen kirin darum

Gorziglia and Kapikian, J. Virol. 66: 4407-4412, 1992.

Guy et al., Proc. Natl. Acad. Sci. USA 89: 10578-10582, 1992.

Helseth et al., J. Virool. 64: 2416-2420, 1990.

Hodgson, Blo/Technology 9: 19-21, 1991

Hoffmann et al., Proteomics 1: 807-818, 2001

Jakoby and Pastan (eds.), Cell Culture. Methods in Enzymology, Vol. 58, 1979.

Caracter area conservation of the

ir itigalikası

ami Amadakan mar

\$100 m \$100 to 100 to 1

Brander Land

ka av med landli

east to trigger again

·高利尔克斯斯 45.

i dikan kama Kamatikana sa katikatikana. Biraho dike aman sa katika

CONTROL OF THE STATE OF THE STATE OF

n Billen élabbárólásoba

Johnson et al., "Peptide Turn Mimetics" in Biotechnology and Pharmacy, Pezzuto et al.,

Eds., Chapman and Hall, New York, 1993.

Johnson et al., J. Virol. 66: 2952-2965, 1992.

Kohler and Milstein, European Journal of Immunology 6: 511-519, 1976.

Kohler and Milstein, Nature 256: 495-499, 1975.

Kubo et al., FEBS Lett. 241: 119, 1988.

Kyte and Doolittle, J. Mol. Biol. 157: 105-132, 1982.

Lai et al., Genome Research 10: 103-113, 2000.

Madzak et al., J. Gen. Virol. 73: 1533-1536, 1992.

Mann and Baltimore, J. Virol. 54: 401-407, 1985.

Margolskee, Curr. Top., Microbiol. Immunol. 158: 67-95, 1992.

Marmur and Doty, J. Mol. Biol. 5: 109, 1962.

35 Teach Lead Matteucci et al., J. Am. Chem. Soc. 103; 3185, 1981.

Miller et al., J. Virol. 62: 4337-4345, 1988.

Miller et al., Mol. Cell. Biol. 5: 431-437, 1985.

Miller, Curr. Top. Microbiol. Immunol. 158: 1-24, 1992.

Moss, Curr. Top. Microbiol. Immunol. 158: 25-38, 1992.

Moss, Proc. Natl. Acad. Sci. USA 93: 11341-11348, 1996.

Munder et al. (Appl. Microbiol. Biotechnol. 52(3): 311-320, 1999.

Muzyczka, Curr. Top. Microbiol. Immunool, 158: 97-129, 1992.

Naldini et al., Science 272: 263-267, 1996.

Oni et al., Gene 89: 279-282: 1990

Orita et al., Proc. Nat. Acad. Sci. USA 86: 2776-2770, 1989.

Page et al., J. Virol. 64: 5270-5276, 1990.

Petropoulos et al., J. Viol. 66: 3391-3397, 1992.

Phizicky and Fields, Microbiol. Rev. 59(1): 94-123, 1994

Quantin et al., Proc. Natl. Acad. Sci. USA 89: 2581-2584, 1992.

Remington's Pharmaceutical Sciences, 18th Ed. (Mack Publishing Company, Easton, PA, U.S.A., 1990.

Rosenfeld et al., Cell 68: 143-155, 1992.

THE RESERVE OF THE PARTY OF THE

Russell and Hirata, Nature Genetics 18: 323-328, 1998.



-66-

R\*OpenE() provision/1389867. beth lites provides-19/13/01

### Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor

t - Armine Priest - Erich Principality (the Morri William) - Asset William (the Color Morris Color Color Color Anno Alexandra 
Strationalism time a completa de la 
ar il-ramo de los las aseste como derdes de los de il como escribar procede propose de la contrarior e de la co

BANTA PONTEN AND AND TO THE PROPERTY OF THE PONTEN AND THE PARTY AND THE PARTY OF THE STANDARD OF THE PARTY O

en de la comparte de

37

a vidinama memi. Makasa adak sa memilikan kenangan kanangan kanangan bagan pingan pingangan bilang berangai k

Charles and the contract of th

tember vertende frende et bled de destal de bled de de de de de de frend bled destal et de day de didente de d

respectation for the contract of the properties of the contract of the contrac

TERROR SAN TENERO DE PARTA DE MARIO PARTA DE CONTRADA DE MARIO DE MARIO DE MARIO DE PARTA DE PARTA DE PARTA DE

and the complete the contract of the contract

am a treating and a trade of the first treating and a treating of the second contract of th

atala watekiza dikentika mwakazi kwa kibina kibina kibi a la ka

a di kacamatan kacamatan da kacamatan kacamatan kacamatan kacamatan kacamatan kacamatan kacamatan kacamatan ka

Laboratory, Cold Spring Harbor, New York, 1989.

Scanlan et al., Int. J. Cancer 75: 652-658, 1998.

Adamsi a Sing.

4**28**0 New 2000 (1966)

Strategies I. Pareste de la compart de la persona de l

TERMINATURE MENTER NEW GRANT BOLLEY

COMPANY THOSE REPORT HOLD TO BE AND A TO A

. Basatawa Karamana kan intersessa sa

Kimanaa Amerika

Schneider et al., Nature Genetics 18: 180-183, 1998.

Shimada et al., J. Clin. Invest. 88: 1043-1047, 1991


Sorge et al., Mol. Cell. Biol. 4: 1730-1737, 1984.


Stratford-Perricaudet et al., Hum. Gene Ther. 1: 241-256, 1990.

Visvader, EMBO J. 11: 4557-4564, 1991

Wilkinson et al., Nucleic Acids Res. 20: 2233-2239, 1992.

Young et al., Nati. Biotechnol. 16(10): 946-950, 1998





and not be denoted by the common of the comm

era dalaman kirikada kana kana kana arabar arawa kirika kana kana kana kana kana kana kana da kanar karaba kana

eraktika Matika kanasa fizatiwa binatika kanasa karatira ina kata endaka Jeografiya kanasa kanatika kenatika k


## 

18 The Marie Principle State of Control (1927)

Sanchare ach earaige cadhride

ar salad dara

in is the family selfs.



- 14 **889. 8**96. €4 0

1.71.085 1.54.6678

anger gan in large the links but in

and a colling the state of the colling of the colli


Taranga ikulikan di 1960-ang abahangan merulikan 1960-ang abahan merulikan di

le a le recombinação de la recombinação de la maisma de la combinação de la combinação de la combinação de la c Figure 2B 

alikinga alikan kengalakan dan mangalah dan mengingan kengalan dan permengan banan kengalah permengan belair b

kardi di Madini andika Metri, adirenti **di Mak**elifak dekak ing makata jidi dikata kasa makelik <mark>ka</mark>as

. . . . .



### Figure 2C

TO STATE OF PARTY THEY AND PARTY ASSOCIATION

THE THE STORM WORKS TO LEASE

A PARTICULAR DE LA CARRACTURA ANTONIO DE LA CARRACTURA DE LA CARRACTURA DE LA CARRACTURA DE LA CARRACTURA DE L

es aposta e p<mark>iù billitere di l'estre di l'estre di l'estre dell'estre dell'estre dell'estre dell'estre dell'estre d</mark>

man Ballandi Balda di Manda mang mang kalanda di Balda d

,其中的激素。2000年,10月10日的1000日,中国10日的10日的10日

SOMEONE SERVICE

antration in the americal test

The Article of the Article State of the Article Sta

West side in the second contraction of the s

emplo (desimilar cini

en Majyaaväsanii miid

17年11日 村前田 (2004年)

**QHADSLENIDESAVAESR** Q9Y365 [SEQ ID NO:2] FKHR1: RRAASMDNNSKEAKSRSR (SEQ ID NO.3)

Service Company of the

\* 22.4% 35 dentity: 6 (33 %) 42.44 m \*\*\*\* 5.51 Strongly similar: 6 (33 %) Weakly similar: 2 (11 %) Different: 4 (22 %)

uu tubanii 9

e martin later i ser exercitato i mai crea c

Marketti mirrikani kara

A 5% Second of many

T Name of the Company 
a a midrossos

Figure 2D

i Maria Baratan da karangan kanggaran da karangan da karangan da karangan karangan karangan karangan karangan k

<u>\( \alpha \) \( \</u>

randis PC kindar virbas Sandaldinas i Sissifiad da Ribera

Traine-Lague Farai (illustriidia) pales territoria cas urbas

lan saktamenta melan in da ke

1886 E388 - 50° VXXX SSS 174 175 F 1720

30 J. A. 380

el o máser elemente

Krisebu kari kalem

STATE OF THE PROPERTY OF THE PARTY OF THE PA

and the property of the late

.ph.clar&7a07**9%**CH2947\$ffe287

er vila imarija etilomikasi.

MALLERY.

Jakara aya bayaya mada b

Tradition ( ) Visiting

on Nime Hearth on

Markethia de Contra market

vanewa vasa kaliferia ka

- Balantino de la Caración de 
0.27

SRAG TVNA.

> EVGWN

ECEAE

VQVPDDQDFRSFR

GRES/

**GGPRPVI** 

EP(

-AAST

PIN<sup>68</sup>EKL

F

<u>പ്</u>

诎

RIWRIL

RAKKLR

œ

ō

\*\*\*\*\***~** 

EPP.

က္ခ

<u>ල</u>

RSCEG

Ζ

IARL AVSIQT EWKOKH

ᇤ

SNVI RKO

RKKWD

一

YDVLHD

Ш

CCDVPA Ž

图

RDVI

급

SWRCP

X GX €

ă

虿 STG

EMDRT

SVWVQAV

TOPA MAI PROMINING SAFE

化硫铁铁 死,是

**S** 

₹ 亙

亙

S

开关 GYL

ō

AM

FLAPK

g

PKWWNKS

ᇫ

D O O 叫

A S

S

EQSPL

**PWLHP** 

kar aki roja siib ja kalivatiyo Jaki koo

Militaratik diskribini bili Yembilik suru

.∵.

ົທ 🐃

ಶ<sub>್</sub>.....

280%

9

S

ळ

ထို

DESAVÆSREERMG 26 .X talah**a**n kalan bahasan

SABA TATOMETER (1986) TOTA SABATA SESTIMBA (1986) SABATA (1986) TATOMETER (1986)

t signer (dan direktif kurus era Malanira i 40 Maja Malandri, aliain dak kilain ka Karali (da Marali

**冷雨** 计位

l Sine All Matter Primari (N. 1984). Sentir in 1994 a matematica e in 1994 in televira (N.

radas (Carini Printeriores a Saltas Parel - Parintenias (Corto Malla el Carini Parel de Calendaria).

y masian dasian u

1.76

eraken et ig samektigden bet

real residentials

rendare se a la compari de 
Carlotta and a state of the second of the se

tin merilinin negriller zon

กรับเพลงสาร์การ์ เหมื่อที่ วีรี่ 4. การ์ และพันธ์

SERVICE PRESENTATION DON'T POR

Same Figure 1

iii.

The complete a

iddar.

) N W

6-36-5-

200

##:0:

80a.034

and the contract of the first of the second

40 au 1526 12 aig |

NAME AND A POST OF THE PARTY OF

AT MATERIAL TRANSPORT STRANGE

化环氧氯化氧氯化铵

480314 4803848 40 Uhr.


No Redian

Comment with the second

a. 11 1982

1.00

100°



aus allawi du assawa<del>n indiana</del>na awa 2001, an aiwa 1949).

andawyki skulus

PART OF SERVICE CONTRACTORS

The The was on the become and

Contraction (1997)


4.5


Alton Brace


15 N. 18 KOBAN, 1806, 69**4, 694, 694** 

Section of the

如然后,就是在歌音点








# Figure 4B

SE CO  $\leq \mathbb{Z}$ Satistia (Santini Art Beini / Beiten **OKHU**  ${\mathfrak O}$  $\overline{S}$ X M S Š rando de la companio YE-QECNGETA FDIARL TVNADV Ó Ã S S S S 云 SERSGVIRVKG. PRKDLVRAVSIO riki ili ka Aran Karania 🛣 <u>≅</u> u han Saarin dan itan Kora asta uu 67 So Verilia  $oldsymbol{\Box}$ AG/ ria estrada en como daderir antida esta en la comenzación. Más en altra ceste ത ⋧ ഗ്∘ ⊗് A B B B B B New and the Levis Heisele ARREST PROPERTY WAS GWN - Vissoria ISMPQLGE IPKYPPRK /DQYVK VDSNVII 2000 11 A SO 1 BY 186 S 📆 karangan sakaran karangan k ivani i 📖 iri 副 8 出 esseried to exec EA KOM ഗ LARSTS SVKHF M. W. M. SKALW rimi kuga ত Ω .v.**abbl**.8v. 交交 ш Ó **}** RS INWAAKNG /NKSSOFL BO GANTO AL COLAS ABO 学社 ш 즢 RSF Ш ADIYMDS ୕ଔ୕୴ Turka MARKANA i3 y ⊗ 1 LYDVLI ū ፳፮ <u>ā</u> ... ". Ab 1969 S. 1968, SWLIN DYVYLRORRDLDMEGI മ് SVOVPI ᠳᡓ **CSPTI** MECCDVPAI \$5000 KGSLF \*\*\*\* ର EMYYFDI. .. :: GVLED RE ш M ত nggy py KCRM Z IRDYN IRDVI  $\mathbf{E}$ S 18 Xx Batter 1 (1) EXK Lit  $\overline{\alpha}$ ပ္သ ◱ againg company of the second Œ Pogl CPKPLKNF PFPMSNI S ഗ ğ <u>a.</u> **க்**டு∗∴ CONTRACTOR SERVICE Mary and Mary and Ø KKTGL MDRT Ö S 유 주 주 주 ngagyariter rainomana de Adria de Asses ᆸ 3/80 Peto Fors1 Petp Fors1 Petp Fors1 NET THE Pctp Fors amina kväiliä läina rassi. ting as the - 1900 a recommenda establisha karantari da 2005 ili. 1 BARROSA NINGERAL making day to entities and manifestation of the property of the contract of 3.0 e skiparanaren eta ira eta bizkara is. Ballang and Ar

\$455.00 miles

100




## 


D. MARKAGE FO


-11.78%/L1886-1

a primi para da di Para Mara Mara da M

. .









"War was walled so it

1.72.13

1:2





LONG THE WILLIAM ST. WILLIAM SAND

1987年中國科学工

States that we have the

TO LEAD TO THE TO THE PERSON OF THE CONTRACTOR OF THE PERSON OF THE PERS

an Sarasista na

1.00

in the Carlos estate and 196

## vyšii varioning Brook (Karlinia) i klain die Broom der Mila XVIII die Karlinia i Verming bie de Karlinia i Kar HER14 Puro + 10 ng/ml EGF a fre lakefring at 18 km tambing spallering 1900 dip din han blocker by retinance and finding bar dinner The Lightness of Salar and Carlotter and the States and the States and the Carlotter and the States and the St ne distribuições de la parameira da principal de la principal de la productiva de la productiva de la productiv u delt jarkling i järgist, millistetensk tojann länd hidelt militar kimmakden mår. Det min i 1900 mente med ka HER14 Fors + 10 ng/ml EGF ut fra e<u>l l'amban</u>a palent par le l'épartiment d<del>es</del> les infecteurs de services de le compartie de l'entre de l'ambande de l'entre de l'ambande de l'entre de l'ambande de l'entre de l'ambande de l'entre de l' ag praese kylykik. Procesa kom rejadnings mili grej kiter, rejaktioner, meteor jake samaji kereje kiter ere kitak e ere kitak a kurden hisrige om er a sala mer a dim rand and base and a 1、表記が、記録数 kodine tra kujih kresita 3.2 TORONO CE LA REPORTA 1 81 1 1 K na samble and bear of comments in a Figure 7C Julio 1885

rakon da desola a rak de kabilar nashi in mindalish ka danshada da da rak bilar da marka ili beshi dalam Mak

one esta en como recitar la mesta en encaritar la colonia de la colonia de la colonia de la colonia de la colon

48.000 MESEN HOUSE ACTIONS

the programme to the second of the

Jane School His Challe

BUTTONING PROPERTY AND ALL AND

INA PRODUČENSKA LA LI

Parkina militar da Parkina Militar da Parkina 
WINDOWS SET SAME SERVED

大·11、1964字符为,第1首《新文》中中《Windawaka Wikawa

History (Krankaraso set Karellinas) as a

2.67 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ± 3.00 ±

coi:

TO SEE AND THE SEE OF THE SEE OF A SEE AND SEE

# 

P-Operigib printy 2002/21888/7 with Eursprov Acc, 13/12/02

The Walter and Eliza Hall Institute of Medical Research 

<120> A novel phosphoprotein

<130> 2589867/EJH

<140> Not yet available

<141> 2002-12-13

<213> peptide

Yetasley

Glu Ser Ala Val Ala Glu Ser Arg Glu Glu Arg Met Gly 

ter Ber (**-2115**) (-18,34) (-1) (ber var errein (2003)), de flance of Alberta (2004) (2005), which are the back of

vojak <213> i peptide, sispon sovan kanakoni kanakoni ini kanakoni kanakoni kanakon kanakon kanakon kanakon ka

Gln His Ala Asp Ser Leu Glu Asn Ile Asp Glu Ser Ala Val Ala Glu 网络**1**维克斯拉拉拉斯克 

·新州南京南南南部城市大学,1970年1986年1986年1986年1987年1月1日1日1日1日日本市大学的大学、中国中国大学的大学。

· 14. 1 2007年 - 1707年 - 12. 14. 14. 14. 14. 14. 15. 14. 15. 14. 15. 14. 15. 14. 15. 14. 15. 14. 15. 14. 15. 14.

The Committee of the Co

\* Ser Arg

<210> 3

<211> 18

<213> peptide

naka Manganga <mark>kangata</mark> palangangan pada kangatan katang pelangan pelangan pada nakang terbahan pelangan pelangan

Arg Arg Ala Ala Ser Met Asp Asn Asn Ser Lys Phe Ala Lys Ser Arg serve servado de la composició de la com

Ser Arg 

<210> 4.

<211> 876

<212> DNA

phosphoprotein

BERTH CARL FRANK FAR FAR FRANK FRANK

医光光性静脉性 數數數 其间的

ala a series isi

eren v Herelli, seen in

### -68-

and seed of the probabilities in the

A DOPERSON OF PARTY OF

The angle of the following and

in 1970 House Burge

	. <b>v</b> .
atggagaage tggeggeete tacagageee caagggeete ggeeggteet gggeegtgag 60	<b>88%</b>
agtgtccagg tgcccgatga ccaagacttt cgcagcttcc ggtcagagtg tgaggctgag 120	
gtgggctgga acctgaccta tagcagggct ggggtgtctg tctgggtgca ggctgtggag 180	ii.
atggatcgga cgctgcacaa gatcaagtgc cggatggagt gctgtgatgt gccagccgag 240 240	×.
acactetacg acgtectaca egacattgag tacegeaaga aatgggacag caacgteatt 300	
gagacttttg acategooog cttgacagto aacgotgacg tgggctatta ctcctggagg 360	lan.
tgtcccaagc ccctgaagaa ccgtgatgtc atcaccctcc gctcctggct ccccatggc 420	
gctgattaca tcattatgaa ctactcagtc aaacatccca aatacccacc tcggaaagac 480	
ttggtccgag ctgtgtccat ccagacgggc tacctcatcc agagcacagg gcccaagagc 540	. ¥
tgegtcatca cctacctggc ccaggtggac cccaaaggct ccttacccaa gtgggtggtg 600	À.
II. STATE TO THE TOTAL TO THE TOTAL TOTAL TOTAL TOTAL TOTAL TO THE TOTAL	ž.
aagtacccg agtggaaaca gaagcacctg cctcacttca agccgtggct gcacccggag *720	
cagagecegt tgeegageet ggegetgteg gagetgtegg tgeageatge ggaeteactg 780	<b>%</b> )
840 840 840 840 840 840 840 840 840 840	&**.
ggcgagggca: gcgacgacga; cacctcgctc. acctga	98.Å
the series to the matter was a restricted as the series of	
*** *** *** *** *** *** *** *** *** **	::
Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg Pro Val	.•
Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly Pro Arg Pro Val	iie.

Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln Asp Phe Arg Ser 25

Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn Leu Thr Tyr Ser N A 2000 A TENNES DE LIGHT A **35** THE PROPERTY LIGHT AND AND LIGHT AND A STREET AND

Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu Met Asp Arg Thr

Teu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp Val Pro Ala Glu 75 80

Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg Lys Lys Trp Asp 

Ser Asn Val Ile Glu Thr Phe Asp Ile Ala Arg Leu Thr Val Asn Ala TO SKIP SEED OF THE SECOND

Sold American State of Control

Asp Val Gly Tyr Tyr Ser Trp Arg Cys Pro Lys Pro Leu Lys Asn Arg 115 120 125

Asp Val Ile Thr Leu Arg Ser Trp Leu Pro Met Gly Ala Asp Tyr Ile 135

Ile Met Asn Tyr Ser Val Lys His Pro Lys Tyr Pro Pro 145 150

Leu Val Arg Ala Val Ser Ile Gln Thr Gly Tyr Leu Ile Gln Ser Thr 

Gly Pro Lys Ser Cys Val Ile Thr Tyr Leu Ala Gln Val Asp Pro Lys David (1966) 18 (1977) (1966) (1966) (1966) (1966) (1966) (1966) (1966) (1966) (1966) (1966) (1966) (1966) (1966)

Gly Ser Leu Pro Lys Trp Val Val Asn Lys Ser Ser Gln Phe Leu Ala 195 200 205

Pro Lys Ala Met Lys Lys Met Tyr Lys Ala Cys Leu Lys Tyr Pro Glu

Trp Lys Gln Lys His Leu Pro His Phe Lys Pro Trp Leu His Pro Glu 235 225 240 230 230 230 230 235 235 235 235 240 240 240

Gln Ser Pro Leu Pro Ser Leu Ala Leu Ser Glu Leu Ser Val Gln His

Ala Asp Ser Leu Glu Asmille Asp Glu Ser Ala Val Ala Glu Ser Arg 260 270 

Glu Glu Arg Met Gly Gly Ala Gly Gly Glu Gly Ser Asp Asp Thr 

Ser Leu Thr

<210× 6

<211> 359

The All Markers of States and Market States and States

Met Ser Thr Arg Ala bys Lys Leu Arg Arg Ile Trp Arg Tle Leu Glu 10

Glu Glu Glu Ser Val Ala Gly Ala Val Gln Thr Leu Leu Leu Arg Ser 

Gln Glu Gly Gly Val Thr Ser Ala Ala Ser Thr Leu Ser Glu Pro

Pro Arg Arg Thr Glu Ser Arg Thr Arg Thr Arg Ala Leu Gly Leu

Pro Thr Leu Pro Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gin Gly an di andrimi adherensa in communica

والمنابي المنبوا المراث والصطوري أترهان والمراز



70%

Pro Arg Pro Val Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln 90 95 Asp Phe Arg Ser Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn 100 105 110 Leu Thr Tyr Ser Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu Met Asp Arg Thr Leu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp Val Pro Ala Glu Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg 145 150 155 Lys Lys Trp Asp Ser Asn Val Tle Glu Thr Phe Asp Ile Ala Arg Leu Thr Val Asn Ala Asp Val Gly Tyr Tyr Ser Trp Arg Cys Pro Lys Pro Thr val Ash Ala Aby val 51, 12 1, 185 190 Leu Lys Asn Arg Asp Val Ile Thr Leu Arg Ser Trp Leu Pro Met Gly
200 205 Ala Asp Tyr Ile Ile Met Asn Tyr Ser Val Lys His Bro Lys Tyr Pro in American and the secretary selection in the Pro Arg Lys Asp Leu Val Arg Ala Val Ser Ile Gln Thr Gly Tyr Leu 235 240 Ile Gln Ser Thr Gly Pro Lys Ser Cys Val Ile Thr Tyr Leu Ala Gln Val Asp Pro Lys Gly Ser Leu Pro Lys Trp Val Val Asn Lys Ser Ser 260 265 270 Gln Phe Leu Ala Pro Lys Ala Met Lys Lys Met Tyr Lys Ala Cys Leu Lys Tyr Pro Glu Trp Lys Gln Lys His Leu Pro His Phe Lys Pro Trp 295 Leu His Pro Glu Gln Ser Pro Leu Pro Ser Leu Ala Leu Ser Glu Leu 305 310 320 320 Ser Val Gin His Ala Asp Ser Leu Glu Asn ile Asp Glu Ser Ala Val 330 Ala Glu Ser Arg Glu Glu Arg Met Gly Gly Ala Gly Gly Glu Gly Ser 350

HOUSE THE DESCRIPTION OF

Asp Asp Asp Thr Ser Leu Thr

The transfer and the last of the transfer of the second

Paris militar in Decisioni distributioni di se di secondo per la constanti di secondo di secondo della constanti

THE RESERVE WILLIAM COMES TO SHOP MAY

<211> 214 <212> PRT

<213> human Selection of the select

Met Glu Leu Ala Ala Gly Ser Phe Ser Glu Glu Gln Phe Trp Glu Ala 

Cys Ala Glu Leu Gln Gln Pro Ala Leu Ala Gly Ala Asp Trp Gln Leu
20 25

Deu Val Glu Thr Ser Gly Ile Ser Ile Tyr Arg Leu Leu Asp Lys Lys

Thr Gly Leu His Glu Tyr Lys Val Phe Gly Val Leu Glu Asp Cys Ser 50 55 60

Pro Thr Leu Leu Ala Asp Ile Tyr Met Asp Ser Asp Tyr Arg Lys Gln 

Trp Asp Gln Tyr Val Lys Glu Leu Tyr Glu Gln Glu Cys Asn Gly Glu
85

Thr Val Val Tyr Trp Glu Val Lys Tyr Pro Phe Pro Met Ser Asn Arg

Asp Tyr Val Tyr Leu Arg Gln Arg Arg Asp Leu Asp Met Glu Gly Arg 

Lys Ile His Val Ile Leu Ala Arg Ser Thr Ser Met Pro Gln Leu Gly

Glu Arg Ser Gly Val The Arg Val Lys Gln Tyr Lys Gln Ser Leu Ala 

Ile Glu Ser Asp Gly Lys Lys Gly Ser Lys Val Phe Met Tyr Tyr Phe 170 175

Asp Asn Pro Gly Gly Gln Ile Pro Ser Trp Leu Ile Asn Trp Ala Ala

Lys Asn Gly Val Pro Asn Phe Leu Lys Asp Met Ala Arg Ala Cys Gln

Asn Tyr Leu Lys Lys Thr

DATED this thirteenth day of December 2002. 

ANTERIOR LA PROPERTIE ANTONIO

The Walter and Eliza Hall Institute of Medical Research

by DAVIES COLLISION CAVE

Patent Attorneys for the Applicant

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

### IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.